WO2019017295A1 - Gelled composition - Google Patents

Gelled composition Download PDF

Info

Publication number
WO2019017295A1
WO2019017295A1 PCT/JP2018/026517 JP2018026517W WO2019017295A1 WO 2019017295 A1 WO2019017295 A1 WO 2019017295A1 JP 2018026517 W JP2018026517 W JP 2018026517W WO 2019017295 A1 WO2019017295 A1 WO 2019017295A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
weight
group
atom
gel composition
Prior art date
Application number
PCT/JP2018/026517
Other languages
French (fr)
Japanese (ja)
Inventor
坂西裕一
山中基資
中野万敬
Original Assignee
株式会社ダイセル
名古屋市
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社ダイセル, 名古屋市 filed Critical 株式会社ダイセル
Priority to JP2019531011A priority Critical patent/JP6878724B2/en
Publication of WO2019017295A1 publication Critical patent/WO2019017295A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Definitions

  • the present invention relates to a gel-like composition containing a fluorinated compound in a high concentration.
  • the gel composition is used in the fields of medicines, quasi drugs, cosmetics and the like.
  • Priority is claimed on Japanese Patent Application No. 201-142253, filed on July 21, 2017, the content of which is incorporated herein by reference.
  • Fluorinated compounds such as fluorocarbons are extremely chemically and biologically inert and have high solubility of gas (eg, oxygen, carbon dioxide, air). For example, under an oxygen atmosphere at 37 ° C., the fluorocarbon can dissolve about 50% of its volume of oxygen. In addition, fluorinated compounds can transport and diffuse gases far away. Thus, fluorinated compounds are of interest as a means for delivering high concentrations of therapeutic gases to tissues and organs.
  • gas eg, oxygen, carbon dioxide, air
  • Patent Document 1 describes that when treating a wound such as a burn, the wound is brought into direct contact with a liquid fluorocarbon, or a bandage, a gauze or the like is brought into contact with a fluorocarbon.
  • a wound such as a burn
  • a bandage, a gauze or the like is brought into contact with a fluorocarbon.
  • Patent Document 2 describes that a gel is obtained by combining a fluorocarbon and a surfactant, separating a fluorocarbon phase concentrated by centrifugation or the like, and redispersing the fluorocarbon phase in an aqueous medium. There is. However, no gel containing fluorocarbon at a concentration of more than 50% by weight was obtained. In addition, complicated work was also a problem.
  • an object of the present invention is to provide a gel-like composition containing a fluorinated compound in a high concentration.
  • Another object of the present invention is to provide a gel-like composition which can be conveniently prepared and which contains a fluorinated compound in a high concentration.
  • a compatible substance obtained by compatibilizing a fluorinated compound with a fluorinated surfactant represented by the following formula (b) has high viscosity. Having high fluidity, being excellent in stability, being extremely chemically and biologically inert, and capable of maintaining high viscosity even when subjected to heat sterilization treatment, and the like; Since it contains in high concentration, it discovered that it was especially excellent in gas solubility or gas permeability.
  • the present invention has been completed based on these findings.
  • the present invention provides a gel-like composition comprising the following compatibilizer.
  • Compatibilizer the following formula (a) (Wherein, R 1 represents a monovalent hydrocarbon group or a monovalent group in which two or more hydrocarbon groups are linked via a linking group, and a hydrogen atom of a hydrogen atom bonded to a carbon atom constituting R 1 30% or more is substituted by a halogen atom containing at least one fluorine atom, X is a halogen atom, a hydrogen atom, a nitrogen atom, or a hydroxyl group, and n is an integer of 1 to 3)
  • Y represents a hydrogen atom or a hydroxyl group) Compatibilized with the compound (B), wherein 75 to 99.9% by weight of the total of the compatibilizer components is a component derived from the compound (A)
  • the present invention also provides that the compound (A) is a perfluoroalkane, a perfluorocycloalkane, a perfluoroether, a perfluoropolyether, a perfluoroamine, and at least one of the fluorine atoms possessed by these compounds is a fluorine atom.
  • the gel-like composition as described above which is a compound substituted with at least one selected from a halogen atom, a hydrogen atom, and a hydroxyl group, and having at least one fluorine atom. Provide the goods.
  • the present invention also provides the gel-like composition as described above, which is a medicine, quasi-drug, cosmetics, or lubricant.
  • the present invention also provides the gel composition, which is a film forming agent.
  • the gel composition of the present invention has high viscosity and no flowability.
  • the gel composition of the present invention is excellent in stability and extremely inactive chemically and biologically.
  • the solubility and permeability of gas for example, oxygen, carbon dioxide, air
  • the gel composition of the present invention is stable to heat, and can maintain its viscosity high even after heat sterilization and the like. Therefore, the gel composition of the present invention can be suitably used as a medicine, quasi-drug, cosmetics, lubricant, etc., and an external preparation applied topically to skin, mucous membrane, etc. (for example, pharmaceuticals) , Quasi-drugs, cosmetics, etc.).
  • the gel composition of the present invention can also be suitably used as a film forming agent.
  • the gel composition of the present invention contains the following compatibilizer.
  • Compatibilized substance a compatible substance of at least one compound (A) represented by the formula (a) and at least one compound (B) represented by the formula (b)
  • Compatible material in which 75 to 99.9% by weight of the total amount of constituents of the product is a component derived from the compound (A)
  • the compound (A) in the present invention is a compound represented by the following formula (a), and is an oil component.
  • R 1 represents a monovalent hydrocarbon group or a monovalent group in which two or more hydrocarbon groups are linked via a linking group, and a hydrogen atom of a hydrogen atom bonded to a carbon atom constituting R 1 30% or more is substituted by a halogen atom containing at least one fluorine atom
  • X is a halogen atom, a hydrogen atom, a nitrogen atom, or a hydroxyl group
  • n is an integer of 1 to 3
  • the hydrocarbon group includes an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, an aromatic hydrocarbon group, and a group to which these are bonded.
  • an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, or a group obtained by combining these is preferable.
  • the monovalent hydrocarbon group for R 1 a monovalent aliphatic hydrocarbon group, a monovalent alicyclic hydrocarbon group, and a monovalent group to which these are bonded are preferable.
  • Carbon number of 1 to 20 (preferably 1 to 10, particularly preferably 1 to 3), such as s-butyl, t-butyl, pentyl, hexyl, decyl, lauryl, myristyl and stearyl groups Alkyl groups; alkenyl groups having 2 to 20 carbon atoms such as vinyl, allyl, 1-butenyl, oleyl and linoleyl; and alkynyls having 2 to 20 carbons such as ethynyl and propynyl. be able to.
  • a C 3-20 alicyclic hydrocarbon group is preferable, and for example, a 3- to 20-membered member such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group or a cyclooctyl group 3 to 15 membered, particularly preferably 5 to 8 membered cycloalkyl group; 3 to 20 membered (preferably 3 to 15 membered, particularly preferably 5 to 8 membered) such as cyclopentenyl group and cyclohexenyl group And the like) perhydronaphthalen-1-yl group, perhydrofluoranthren-3-yl group, perfluorodecalin-1-yl group, perfluoroperhydrophenanthren-1-yl group, norbornyl group, Adamantyl group, tricyclo [5.2.1.0 2,6 ] decan-8-yl group, t
  • Examples of monovalent hydrocarbon groups in which an aliphatic hydrocarbon group and an alicyclic hydrocarbon group are bonded include cycloalkyl substituted alkyl groups such as a cyclopentylmethyl group, a cyclohexylmethyl group and a 2-cyclohexylethyl group (for example, C 3 -20 cycloalkyl substituted C 1-4 alkyl group etc.) and the like.
  • monovalent hydrocarbon groups of R 1 monovalent saturated aliphatic hydrocarbon groups, monovalent saturated alicyclic hydrocarbon groups, and monovalent radicals having these combined are particularly preferable.
  • linking group for example, a carbonyl group (-CO-), an ether bond (-O-), a thioether bond (-S-), an ester bond (-COO-), an amide bond (-CONH-), a carbonate bond ( -OCOO-) etc. can be mentioned.
  • halogen atom in addition to a fluorine atom, a chlorine atom, a bromine atom and an iodine atom are included.
  • 30% or more of the hydrogen atoms bonded to the monovalent hydrocarbon group or the monovalent group bonded to two or more hydrocarbon groups via a linking group are substituted with a halogen atom containing at least one fluorine atom Among them, it is preferable that at least 50% (particularly preferably at least 80%, particularly preferably at least 90%) is substituted by at least one halogen atom containing fluorine atom.
  • the upper limit is 100%.
  • perfluoroalkane examples include perfluoromethane, perfluoroethane, perfluorobutane, perfluoroisobutane, perfluoroisopropane and the like.
  • perfluorocycloalkane examples include perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluoroisopropyldecalin, perfluoro-n-butyldecalin, perfluoromethyladamantane, perfluorodimethyladamantane, perfluoromethylmethyl.
  • CF 3 O CF 2 CF 2 O
  • perfluoroamines examples include N (C 3 F 7 ) 3 , N (C 4 F 9 ) 3 (boiling point 178 ° C.), N (C 5 F 11 ) 3 and perfluoro-N-methylperhydroquinoline. And perfluoro-N-methylperhydroisoquinoline and the like.
  • the molecular weight of the compound (A) is, for example, 50 to 10000, preferably 100 to 8000, particularly preferably 500 to 8000, and most preferably 1000 to 7000.
  • the compound (A) has a boiling point of, for example, 140 ° C. or more, preferably 200 ° C. or more (eg, 200 to 300 ° C.) at normal pressure, which is less volatile at room temperature and suitable for use in the form of external preparations Preferred.
  • the compound (B) in the present invention is a compound represented by the following formula (b) and having a perfluoroalkyl chain moiety and a hydrocarbon chain moiety, and is a compound having a surface activity ability (ie, a surfactant). is there.
  • the compound (B) in the present invention is used as a gelling agent for the above compound (A).
  • m1 and m2 are the same or different and each represents an integer of 3 to 22.
  • Y represents a hydrogen atom or a hydroxyl group
  • M1 in the formula (b) represents an integer of 3 to 22.
  • it is preferably an integer of 5 to 18, particularly preferably an integer of 7 to 15.
  • M2 in the formula (b) represents an integer of 3 to 22.
  • it is preferably an integer of 5 to 18, particularly preferably an integer of 6 to 15.
  • m1 + m2 is, for example, an integer of 10 to 40, preferably an integer of 12 to 35, and particularly preferably an integer of 15 to 30.
  • Specific examples of the compound (B) when Y is a hydrogen atom are 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8 9, 9, 10, 10-Henicosa fluorohenicosan, 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8 9, 9, 10, 10-Henicosa fluoroicosane, 1, 1, 1, 2, 2, 3, 3, 4, 5, 4, 5, 6, 7, 7, 8, 8, 9,9,10,10-Henicosa fluoroheptadecane, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoroheptadecane, 1,1 1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotridecane, 1,1,1,2,2,3,3,4,4,5,5 , 6, 6, 7, 7, 8, 8, 9, 9, 10, 10, 11, 1 , 12, 12-Pentacosafluorotetracosane, 1, 1, 1, 2, 2, 3, 3, 4, 5, 4, 5, 6, 6, 7, 7, 8, 8, 9, 9, 10 10, 11, 11, 12, 12, 12-penta
  • the compound (B) is a compound comprising a perfluoroalkyl chain moiety and a hydrocarbon chain moiety as described above, and the perfluoroalkyl chain moiety has affinity to the compound (A). Therefore, when compound (B) is added to compound (A) and compatibilized, compound (B) is assembled with compound (A) with the perfluoroalkyl chain part on the outside and the hydrocarbon chain part on the inside. It is possible to form a body (for example, a string-like association), and the assembly forms a network in the compound (A), whereby the compound (A) is gelled. In addition, since the inside of the assembly has a hydrophilic environment, it is also possible to enclose, for example, a water-soluble substance.
  • Compound (B) has lower hemolytic activity and lower toxicity as compared to hydrocarbons similar to Compound (B) (JG Riess, Adv. Mat., 3: 249-251 (1991)). Therefore, it is excellent in biocompatibility and can be used in the fields of pharmaceuticals, quasi-drugs and cosmetics.
  • the compound (B) can be produced, for example, by the following method and the like, but is not limited to this production method.
  • the perfluoroalkyl iodide represented by the formula (1) is used in the following method, it is also possible to use perfluoroalkyl bromide or perfluoroalkyl chloride instead.
  • Y, m1 and m2 are the same as above.
  • step [1] is a step of reacting (radical reaction) the perfluoroalkyl iodide represented by the formula (1) with the unsaturated compound represented by the formula (2).
  • the compound represented by the said Formula (3) is obtained through the said process [1].
  • the above reaction may be carried out without a solvent, but it is preferable to carry out the reaction in the presence of a solvent in terms of facilitating the production operation.
  • the solvent is particularly limited as long as it is excellent in the solubility of the perfluoroalkyl iodide represented by the formula (1) and the unsaturated compound represented by the formula (2) and does not inhibit these radical reactions.
  • aromatic hydrocarbons such as toluene; ethers such as THF; esters such as butyl acetate; ketones such as methyl ethyl ketone; alcohols such as propanol; and the like. These can be used singly or in combination of two or more.
  • the amount of the solvent used is, for example, about 50 to 300% by weight, preferably about 100% by weight, based on the total amount of the perfluoroalkyl iodide represented by the formula (1) and the unsaturated compound represented by the formula (2). It is ⁇ 300% by weight. When the amount of the solvent used exceeds the above range, the concentration of the reaction component tends to be low, and the reaction rate tends to be low.
  • radical initiator examples include, for example, azo compounds [for example, 2,2′-azobis (isobutyronitrile), 2,2′-azobis (2,4-dimethylvaleronitrile, azobiscyanovaleric acid, 2,2′- Azobis (2-amidinopropane) hydrochloride, 2,2′-azobis (2-amidinopropane) acetate, etc.], inorganic peroxides (eg, persulfates such as potassium persulfate, sodium persulfate, ammonium persulfate, etc.) Hydrogen peroxide), organic peroxides [eg, benzoyl peroxide, di-t-butyl peroxide, cumene hydroperoxide, bis (2-ethoxyethyl) peroxydicarbonate], redox catalysts, etc. These can be used alone or
  • the atmosphere for the reaction is not particularly limited as long as the reaction is not inhibited.
  • any of an air atmosphere, a nitrogen atmosphere, an argon atmosphere and the like may be used.
  • the reaction temperature can be appropriately adjusted depending on the solvent used and is, for example, about 60 to 120 ° C.
  • the reaction time is, for example, about 0.1 to 20 hours.
  • an aging step may be provided.
  • the ripening temperature is, for example, about 60 to 100 ° C.
  • the ripening time is, for example, about 0.1 to 5 hours.
  • the reaction can be carried out by any method such as batch system, semi-batch system, continuous system and the like.
  • the obtained reaction product can be separated and purified by separation means such as filtration, concentration, distillation, extraction, crystallization, adsorption, recrystallization, column chromatography, or a combination of these.
  • the step [2] is a step of subjecting the compound represented by the formula (3) obtained through the above step [1] to a reduction treatment to obtain a compound (B).
  • the reduction treatment of the compound represented by the formula (3) can be carried out by a well-known and commonly used method, for example, a reduction method using a hydrogenation reducing agent.
  • Examples of the hydrogenation reducing agent include metals such as zinc and tin; aluminum hydride, lithium aluminum hydride, sodium borohydride, lithium borohydride, diisobutylaluminum hydride, dibutyltin hydride, tributyltin hydride, hydrogen Diphenyltin halide, triphenyltin hydride, zinc borohydride, diborane and the like can be mentioned.
  • the reduction treatment may be carried out in the presence of a solvent
  • a solvent examples include alcohols such as methanol, ethanol and isopropanol and their aqueous solutions, diglyme and their aqueous solutions, sulfolane, pyridine, DMSO, THF and the like. it can. These can be used singly or in combination of two or more.
  • the amount of the solvent used is, for example, about 50 to 300% by weight, preferably 100 to 300% by weight, relative to the compound represented by the formula (3).
  • the amount of the solvent used exceeds the above range, the concentration of the reaction component tends to be low, and the reaction rate tends to be low.
  • the atmosphere for the reaction is not particularly limited as long as the reaction is not inhibited.
  • any of an air atmosphere, a nitrogen atmosphere, an argon atmosphere and the like may be used.
  • the reaction temperature can be appropriately adjusted depending on the solvent used and is, for example, about 60 to 100 ° C.
  • the reaction time is, for example, about 0.1 to 20 hours.
  • an aging step may be provided.
  • the aging temperature is, for example, about 10 to 40 ° C.
  • the aging time is, for example, about 0.5 to 5 hours.
  • the reaction can be carried out by any method such as batch system, semi-batch system, continuous system and the like.
  • the obtained reaction product can be separated and purified by separation means such as filtration, concentration, distillation, extraction, crystallization, adsorption, recrystallization, column chromatography, or a combination of these.
  • the gel composition of the present invention comprises the step of compatibilizing at least one of the compound (A) represented by the formula (a) and at least one of the compound (B) represented by the formula (b) It can be manufactured simply.
  • the compound (A) and the compound (B) are compatibilized by, for example, heat mixing at 80 to 200 ° C. (preferably 100 to 180 ° C., particularly preferably 120 to 160 ° C.) to form a compatibilized substance .
  • the compound (A) and the compound (B) may be prepared by mixing the compound (A) and the compound (B) in advance and then heating the compound (A) to make the compound compatible.
  • the compound (B) may be gradually added thereto to be compatible.
  • stirring processing at the time of heating. If necessary, a degassing treatment (for example, degassing treatment by centrifugation at room temperature) may be performed.
  • the time required for heating is, for example, about 3 to 60 minutes (preferably 10 to 30 minutes).
  • room temperature eg, 1 to 30 ° C.
  • the cooling may be gradual cooling at room temperature or may be rapid cooling by ice cooling or the like.
  • the amount of compound (B) used is, for example, 0.1 to 33 parts by weight, preferably 0.5 to 25 parts by weight, particularly preferably 1 to 18 parts by weight, per 100 parts by weight of compound (A). Preferably, it is 2 to 11 parts by weight.
  • the weight ratio of the amount of compound (A) to compound (B) used is, for example, 75:25 to 99.9: 0.1, preferably 80:20 to 99.5: 0. .5, particularly preferably 85:15 to 99: 1, most preferably 90:10 to 98: 2.
  • the compound (B) has excellent surfactant activity with respect to the compound (A), so that the compound (A) can be gelled by using a very small amount.
  • the proportion of the component derived from the compound (A) in the total amount of constituents of the obtained compatible material is 75 to 99.9% by weight, preferably 80 to 99.5% by weight, particularly preferably 85 to 99% by weight. Most preferably, it is 90 to 98% by weight.
  • the proportion of the component derived from compound (B) in the total amount of the components of the compatible material is 0.1 to 25% by weight, preferably 0.5 to 20% by weight, particularly preferably 1 to 15% by weight. %, Most preferably 2 to 10% by weight.
  • the proportion of the component derived from the compound (A) in the gel composition of the present invention is, for example, 30 to 99.9% by weight, preferably 50 to 99.9%, more preferably 75 to 99.9%. More preferably, it is 80 to 99.5% by weight, particularly preferably 85 to 99% by weight, and most preferably 90 to 98% by weight.
  • the proportion of the component derived from compound (B) in the total amount of gel composition of the present invention is, for example, 0.1 to 70% by weight, preferably 0.1 to 50% by weight, more preferably 0.1 to 25%. % By weight, more preferably 0.5 to 20% by weight, particularly preferably 1 to 15% by weight, most preferably 2 to 10% by weight.
  • the gel composition of the present invention may contain other components as needed as long as the effects of the present invention are not impaired, besides the compatibilizer of the compound (A) and the compound (B).
  • the proportion of the compatibilizer of the compound (A) and the compound (B) in the whole gel composition of the present invention is, for example, 5% by weight or more, preferably 10% by weight or more. It is preferably at least 20% by weight, more preferably at least 30% by weight, still more preferably at least 40% by weight, still more preferably at least 50% by weight, still more preferably at least 60% by weight, particularly preferably at least 70% by weight, particularly preferably It is at least 80% by weight, most preferably at least 90% by weight.
  • the upper limit is 100% by weight. That is, the gel composition of the present invention may consist of only the compatibilizer of the compound (A) and the compound (B).
  • any of an oil-based component and an aqueous component may be sufficient, and it can adjust suitably according to a use.
  • the gel composition of the present invention when used as a drug, quasi drug or cosmetic product, it can contain, without particular limitation, components usually contained in the drug, quasi drug or cosmetic product.
  • the gel composition of the present invention when used as a drug, quasi-drug or cosmetic product, it contains a substance (eg, growth factor, antibiotic, nutrient, etc.) to be released at an appropriate site. It may be done.
  • the gel composition of the present invention may contain other oily components in addition to the compound (A), but the content of the oily components other than the compound (A) (when two or more kinds are contained,
  • the total amount is, for example, 60% by weight or less, preferably 50% by weight or less, more preferably 40% by weight or less, still more preferably 30% by weight or less, particularly preferably 20% by weight or less of the total amount of oil components contained in the gel composition Particularly preferably, it is at most 10% by weight, most preferably at most 5% by weight.
  • the lower limit is 0% by weight.
  • the gel composition of the present invention may contain a surfactant other than the compound (B), but the content of the surfactant other than the compound (B) (in the case of containing two or more, the total amount thereof ) Is, for example, 40% by weight or less, preferably 30% by weight or less, more preferably 20% by weight or less, particularly preferably 10% by weight or less, most preferably 5% by weight or less of the total amount of surfactant contained in the gel composition It is.
  • the lower limit is 0% by weight.
  • a surfactant is a compound having a high affinity functional group to an oil component and a low affinity functional group in combination.
  • the gel composition of the present invention has high viscosity and no flowability.
  • the viscosity at 25 ° C. [at a shear rate of 0.5 s ⁇ 1 ] is, for example, 10 Pa ⁇ s or more, preferably 20 Pa ⁇ s or more.
  • the gel composition of the present invention contains the compound (B) having an excellent surface activity ability, and therefore, when the compound (A) is transparent, it exists as a transparent gel composition. Therefore, the gel composition of the present invention is excellent in appearance.
  • the gel composition of the present invention is excellent in stability and extremely inactive chemically and biologically. Further, they are stable to heat, and the compatibilizer contained in the gel-like composition of the present invention even after heat sterilization etc., that is, an aggregate of compound (A) and compound (B) (for example, a string (Like aggregate) can maintain high viscosity without reducing molecular weight. Therefore, it can be used also in the field where high hygiene management is required.
  • the gel composition of the present invention contains a high concentration of the compound (A) excellent in the solubility of gas (for example, oxygen, carbon dioxide, air), and therefore means for delivering a high concentration of gas to the application site It can be suitably used as
  • the gel-like composition of the present invention contains a compound (A) which is both hydrophobic and oleophobic and is excellent in gas permeability at a high concentration. Therefore, by applying and drying the gel-like composition of the present invention, it is possible to form a protective film having both hydrophobicity and oleophobicity while having gas (especially oxygen) permeability. Accordingly, the gel composition of the present invention can also be suitably used as a film forming agent.
  • the gel-like composition of the present invention has lubricating properties, has an effect of improving sliding and suppressing friction.
  • the gel composition of the present invention can be suitably used as a medicine, quasi-drug, cosmetics, or lubricant.
  • the gel composition of the present invention is used as a medicine, quasi-drug, cosmetics, or lubricant, it has high viscosity and does not have fluidity, so it is excellent in usability or applicability.
  • the gel composition of the present invention is a pharmaceutical product, quasi-drug or cosmetic product, it may be used by applying directly to the skin, patch applied to the skin, transdermal patch, plaster, bandage It may be used by impregnating with a support such as an agent.
  • the gel composition of the present invention when it is applied to the affected area, the affected area is protected from contamination and dust while maintaining the permeability of gas (especially oxygen). Can form a coating.
  • the gel composition of the present invention is a cosmetic, if it is applied to the skin, while maintaining the permeability of gas (especially oxygen) (that is, without inhibiting skin respiration), the skin surface And the like can be concealed to form a film capable of evenly conditioning the skin surface.
  • Step 2 The above 12,12,13,13,14,14,15,15,16,16,17,17,18,19,19,20,20,21,21,21-Heniko Add 7.030 g (8.6 mmol) of safluoro-10-iodohenicosan-1-ol and ethanol, and introduce it through a flask in which argon gas is bubbled in concentrated hydrochloric acid using an inlet tube, and exhaust The side was passed through an alkali trap and vigorously stirred in an 80 ° C. oil bath. 0.3 g of powdered zinc was added to the reaction mixture in six portions. The mixture was heated at 40 ° C. in an oil bath and bubbling of argon gas was stopped.
  • the precipitated white precipitate is separated by suction filtration, dried by an evaporator, and represented by the following formula (b-1), as a white solid gelling agent (1) (12, 12, 13, 13, 14, 14, 15, 15, 16, 16, 17, 17, 18, 18, 19, 19, 20, 20, 21, 21, 21-Henicosa fluorohenicosan-1-ol) 4.83 g (7. 0 mmol, yield 82%) was obtained.
  • the structure of the reaction product was confirmed by 1 H-NMR.
  • 1 H-NMR (400 MHz, CDCl 3 ): ⁇ 3.65 (t, 2 H), 2.05 (m, 2 H), 1.56 (m, 4 H), 1.29 (m, 14 H), 1.20 (t, 1 H)
  • Example 1 1 cm 3 of polyperfluoromethyl isopropyl ether (molecular weight 1500) is added to a test tube, to which 5% by weight of the gelling agent (1) is added and mixed, and heated and stirred at 150 ° C. It was dissolved and cooled to 25 ° C. to obtain a composition (content of polyperfluoromethyl isopropyl ether (molecular weight 1500): 95% by weight).
  • Gelling agent (7) Di Benzylidene sorbitol, manufactured by Shin Nippon Rika Co., Ltd., trade name “Gelall D”
  • Gelling agent (8) inulin stearic acid ester, manufactured by Chiba Flour Mills Co., Ltd., trade name "Leopard ISL2"
  • the compound (A) is a perfluoroalkane, a perfluorocycloalkane, a perfluoroether, a perfluoropolyether, a perfluoroamine, and a halogen atom in which at least one of the fluorine atoms of these compounds is other than a fluorine atom,
  • the gel-like compound according to [1] which is a compound substituted with at least one selected from a hydrogen atom and a hydroxyl group, and having at least one fluorine atom. Composition.
  • a compound wherein the compound (B) is represented by the formula (b), m1 in the formula (b) is an integer of 7 to 15, m2 is an integer of 5 to 15, and m1 + m2 is an integer of 15 to 30 The gel composition according to any one of [1] to [7].
  • the compound (B) is at least one selected from the compounds represented by formulas (b-1), (b-2), (b-3), (b-4) and (b-5) The gel composition according to any one of [1] to [7], which is one type.
  • the proportion of the compatibilizer of compound (A) and compound (B) in the total amount of gel-like composition is 5 to 100% by weight (the lower limit is preferably 10% by weight, more preferably 20% by weight, further preferably) Is 30% by weight, more preferably 40% by weight, more preferably 50% by weight, more preferably 60% by weight, particularly preferably 70% by weight, particularly preferably 80% by weight, most preferably 90% by weight)
  • the gel composition according to any one of [1] to [10].
  • the proportion of the compound (A) in the total amount of oily components contained in the gel-like composition is 40% by weight or more (preferably 50% by weight or more, more preferably 60% by weight or more, still more preferably 70% by weight or more)
  • the proportion of the compound (B) in the total amount of compounds having a high affinity functional group to an oily component and a high affinity functional group to an aqueous component contained in the gel-like composition is 40% by weight or more (Preferably 50 wt% or more, more preferably 60 wt% or more, still more preferably 70 wt% or more, particularly preferably 80 wt% or more, particularly preferably 90 wt% or more, most preferably 95 wt% or more)
  • the gel composition of the present invention has high viscosity and no flowability. In addition, they are excellent in stability and extremely inactive chemically and biologically. Furthermore, the solubility and permeability of the gas are excellent. Furthermore, the gel composition of the present invention is stable to heat, and can maintain its viscosity high even after heat sterilization and the like. Therefore, it can be suitably used as pharmaceuticals, quasi-drugs, cosmetics, lubricants and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided is a gelled composition containing a fluorinated compound at a high concentration. This gelled composition includes a miscible article. The miscible article is: a compound (A) represented by formula (a) (in the formula: R1 represents a monovalent hydrocarbon group or a monovalent group in which 2 or more hydrocarbon groups are bonded together via a linking group, and at least 30% of the hydrogen atoms bonded to the carbon atoms constituting R1 are substituted by at least one halogen atom such as a fluorine atom; X represents a halogen atom, a hydrogen atom, a nitrogen atom, or a hydroxy group; and n represents an integer of 1 to 3); and a compound (B) represented by formula (b) (in the formula: m1 and m2 are the same or different from each other, and represent an integer of 3 to 22; and Y represents a hydrogen atom or a hydroxy group). 75-99.9 wt% of the total amount of the constituents of the miscible article is derived from compound (A).

Description

ゲル状組成物Gel composition
 本発明は、フッ素化化合物を高濃度に含有するゲル状組成物に関する。前記ゲル状組成物は、医薬品、医薬部外品、化粧品等の分野において用いられる。本願は、2017年7月21日に日本に出願した、特願2017-142253号の優先権を主張し、その内容をここに援用する。 The present invention relates to a gel-like composition containing a fluorinated compound in a high concentration. The gel composition is used in the fields of medicines, quasi drugs, cosmetics and the like. Priority is claimed on Japanese Patent Application No. 201-142253, filed on July 21, 2017, the content of which is incorporated herein by reference.
 フルオロカーボン等のフッ素化化合物は、化学的および生物学的に極めて不活性である上、ガス(例えば、酸素、二酸化炭素、空気)の溶解度が高いという特性を有する。例えば、37℃の酸素雰囲気下では、フルオロカーボンは体積の約50%の酸素を溶解することができる。さらに、フッ素化化合物は、ガスを輸送し遠くに拡散させることができる。従って、フッ素化化合物は、組織や器官へ高濃度の治療用ガスを送達するための手段として注目されている。 Fluorinated compounds such as fluorocarbons are extremely chemically and biologically inert and have high solubility of gas (eg, oxygen, carbon dioxide, air). For example, under an oxygen atmosphere at 37 ° C., the fluorocarbon can dissolve about 50% of its volume of oxygen. In addition, fluorinated compounds can transport and diffuse gases far away. Thus, fluorinated compounds are of interest as a means for delivering high concentrations of therapeutic gases to tissues and organs.
 特許文献1には、熱傷などの創傷の治療の際に、創傷に液状のフルオロカーボンを直接接触させるか、或いは包帯やガーゼ等にフルオロカーボンを含ませて接触させることが記載されている。しかし、使用性の点で問題があった。 Patent Document 1 describes that when treating a wound such as a burn, the wound is brought into direct contact with a liquid fluorocarbon, or a bandage, a gauze or the like is brought into contact with a fluorocarbon. However, there was a problem in terms of usability.
 そして、使用性を向上する方法としては、フルオロカーボン等のフッ素化化合物を適度に増粘することが考えられる。フルオロカーボン等のフッ素化化合物の増粘には界面活性剤を使用することが知られている。 And as a method of improving usability, it is conceivable to appropriately thicken a fluorinated compound such as fluorocarbon. It is known to use surfactants to thicken fluorinated compounds such as fluorocarbons.
 特許文献2には、フルオロカーボンと界面活性剤とを複合化し、遠心分離などによって濃縮されたフルオロカーボン相を分離し、このフルオロカーボン相を水性媒体に再分散することによってゲルが得られることが記載されている。しかし、フルオロカーボンを50重量%を超える濃度で含有するゲルは得られなかった。また、作業が繁雑であることも問題であった。 Patent Document 2 describes that a gel is obtained by combining a fluorocarbon and a surfactant, separating a fluorocarbon phase concentrated by centrifugation or the like, and redispersing the fluorocarbon phase in an aqueous medium. There is. However, no gel containing fluorocarbon at a concentration of more than 50% by weight was obtained. In addition, complicated work was also a problem.
米国特許第4366169号明細書U.S. Pat. No. 4,366,169 特開昭63-100928号公報Japanese Patent Application Laid-Open No. 63-100928
 従って、本発明の目的は、フッ素化化合物を高濃度に含有するゲル状組成物を提供することにある。
 本発明の他の目的は、簡便に調製することができ、フッ素化化合物を高濃度に含有するゲル状組成物を提供することにある。
Accordingly, an object of the present invention is to provide a gel-like composition containing a fluorinated compound in a high concentration.
Another object of the present invention is to provide a gel-like composition which can be conveniently prepared and which contains a fluorinated compound in a high concentration.
 本発明者等は上記課題を解決するため鋭意検討した結果、フッ素化化合物を、下記式(b)で表されるフッ素系界面活性剤と相溶させることにより得られる相溶物は高い粘性を有し、流動性を有さないこと、安定性に優れ、化学的、生物学的に極めて不活性であり、加熱滅菌処理等を行っても粘性を高く維持することができること、フッ素化化合物を高濃度に含有するため、ガスの溶解性若しくはガスの透過性に特に優れることを見いだした。本発明はこれらの知見に基づいて完成させたものである。 The inventors of the present invention conducted intensive studies to solve the above problems, and as a result, a compatible substance obtained by compatibilizing a fluorinated compound with a fluorinated surfactant represented by the following formula (b) has high viscosity. Having high fluidity, being excellent in stability, being extremely chemically and biologically inert, and capable of maintaining high viscosity even when subjected to heat sterilization treatment, and the like; Since it contains in high concentration, it discovered that it was especially excellent in gas solubility or gas permeability. The present invention has been completed based on these findings.
 すなわち、本発明は、下記相溶物を含むゲル状組成物を提供する。
 相溶物:下記式(a)
Figure JPOXMLDOC01-appb-C000003
(式中、R1は1価の炭化水素基、又は2個以上の炭化水素基が連結基を介して結合した1価の基を示し、R1を構成する炭素原子に結合する水素原子の30%以上は少なくとも1つのフッ素原子を含むハロゲン原子で置換されている。Xはハロゲン原子、水素原子、窒素原子、又は水酸基を示し、nは1~3の整数を示す)
で表される化合物(A)と、下記式(b)
Figure JPOXMLDOC01-appb-C000004
(式中、m1、m2は、同一又は異なって、3~22の整数を示す。Yは水素原子又は水酸基を示す)
で表される化合物(B)との相溶物であって、前記相溶物構成成分全量の75~99.9重量%が化合物(A)由来の成分である相溶物
That is, the present invention provides a gel-like composition comprising the following compatibilizer.
Compatibilizer: the following formula (a)
Figure JPOXMLDOC01-appb-C000003
(Wherein, R 1 represents a monovalent hydrocarbon group or a monovalent group in which two or more hydrocarbon groups are linked via a linking group, and a hydrogen atom of a hydrogen atom bonded to a carbon atom constituting R 1 30% or more is substituted by a halogen atom containing at least one fluorine atom, X is a halogen atom, a hydrogen atom, a nitrogen atom, or a hydroxyl group, and n is an integer of 1 to 3)
And a compound (A) represented by the following formula (b)
Figure JPOXMLDOC01-appb-C000004
(Wherein, m1 and m2 are the same or different and each represents an integer of 3 to 22. Y represents a hydrogen atom or a hydroxyl group)
Compatibilized with the compound (B), wherein 75 to 99.9% by weight of the total of the compatibilizer components is a component derived from the compound (A)
 本発明は、また、化合物(A)が、パーフルオロアルカン、パーフルオロシクロアルカン、パーフルオロエーテル、パーフルオロポリエーテル、パーフルオロアミン、及びこれらの化合物が有するフッ素原子の少なくとも1つがフッ素原子以外のハロゲン原子、水素原子、及び水酸基から選択される少なくとも1種で置換された化合物であって、少なくとも1つのフッ素原子を有する化合物、から選択される少なくとも1種の化合物である、前記のゲル状組成物を提供する。 The present invention also provides that the compound (A) is a perfluoroalkane, a perfluorocycloalkane, a perfluoroether, a perfluoropolyether, a perfluoroamine, and at least one of the fluorine atoms possessed by these compounds is a fluorine atom. The gel-like composition as described above, which is a compound substituted with at least one selected from a halogen atom, a hydrogen atom, and a hydroxyl group, and having at least one fluorine atom. Provide the goods.
 本発明は、また、医薬品、医薬部外品、化粧品、又は潤滑剤である、前記のゲル状組成物を提供する。 The present invention also provides the gel-like composition as described above, which is a medicine, quasi-drug, cosmetics, or lubricant.
 本発明は、また、被膜形成剤である、前記のゲル状組成物を提供する。 The present invention also provides the gel composition, which is a film forming agent.
 本発明のゲル状組成物は、高い粘性を有し、流動性を有さない。また、本発明のゲル状組成物は安定性に優れ、化学的、生物学的に極めて不活性である。更に、ガス(例えば、酸素、二酸化炭素、空気)の溶解性や透過性に優れる。更にまた、本発明のゲル状組成物は熱に安定であり、加熱滅菌処理等を行っても粘性を高く維持することができる。
 そのため、本発明のゲル状組成物は、医薬品、医薬部外品、化粧品、又は潤滑剤等として好適に使用することができ、とりわけ、皮膚や粘膜等の局所へ適用する外用剤(例えば、医薬品、医薬部外品、化粧品等)として好適に使用することができる。本発明のゲル状組成物は、その他、被膜形成剤としても好適に使用することができる。
The gel composition of the present invention has high viscosity and no flowability. In addition, the gel composition of the present invention is excellent in stability and extremely inactive chemically and biologically. Furthermore, the solubility and permeability of gas (for example, oxygen, carbon dioxide, air) are excellent. Furthermore, the gel composition of the present invention is stable to heat, and can maintain its viscosity high even after heat sterilization and the like.
Therefore, the gel composition of the present invention can be suitably used as a medicine, quasi-drug, cosmetics, lubricant, etc., and an external preparation applied topically to skin, mucous membrane, etc. (for example, pharmaceuticals) , Quasi-drugs, cosmetics, etc.). The gel composition of the present invention can also be suitably used as a film forming agent.
 [ゲル状組成物]
 本発明のゲル状組成物は、下記相溶物を含む。
 相溶物:式(a)で表される化合物(A)の少なくとも1種と、式(b)で表される化合物(B)の少なくとも1種との相溶物であって、前記相溶物構成成分全量の75~99.9重量%が化合物(A)由来の成分である相溶物
[Gel-like composition]
The gel composition of the present invention contains the following compatibilizer.
Compatibilized substance: a compatible substance of at least one compound (A) represented by the formula (a) and at least one compound (B) represented by the formula (b) Compatible material in which 75 to 99.9% by weight of the total amount of constituents of the product is a component derived from the compound (A)
 (化合物(A))
 本発明における化合物(A)は、下記式(a)で表される化合物であり、油性成分である。
Figure JPOXMLDOC01-appb-C000005
(式中、R1は1価の炭化水素基、又は2個以上の炭化水素基が連結基を介して結合した1価の基を示し、R1を構成する炭素原子に結合する水素原子の30%以上は少なくとも1つのフッ素原子を含むハロゲン原子で置換されている。Xはハロゲン原子、水素原子、窒素原子、又は水酸基を示し、nは1~3の整数を示す)
(Compound (A))
The compound (A) in the present invention is a compound represented by the following formula (a), and is an oil component.
Figure JPOXMLDOC01-appb-C000005
(Wherein, R 1 represents a monovalent hydrocarbon group or a monovalent group in which two or more hydrocarbon groups are linked via a linking group, and a hydrogen atom of a hydrogen atom bonded to a carbon atom constituting R 1 30% or more is substituted by a halogen atom containing at least one fluorine atom, X is a halogen atom, a hydrogen atom, a nitrogen atom, or a hydroxyl group, and n is an integer of 1 to 3)
 前記炭化水素基には、脂肪族炭化水素基、脂環式炭化水素基、芳香族炭化水素基、及びこれらの結合した基が含まれる。本発明においては、なかでも、脂肪族炭化水素基、脂環式炭化水素基、又はこれらの結合した基が好ましい。 The hydrocarbon group includes an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, an aromatic hydrocarbon group, and a group to which these are bonded. In the present invention, among them, an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, or a group obtained by combining these is preferable.
 従って、R1における1価の炭化水素基としては、1価の脂肪族炭化水素基、1価の脂環式炭化水素基、及びこれらの結合した1価の基が好ましい。 Therefore, as the monovalent hydrocarbon group for R 1 , a monovalent aliphatic hydrocarbon group, a monovalent alicyclic hydrocarbon group, and a monovalent group to which these are bonded are preferable.
 1価の脂肪族炭化水素基としては、炭素数1~20(=C1-20)の脂肪族炭化水素基が好ましく、例えば、メチル基、エチル基、プロピル基、イソプロピル基、ブチル基、イソブチル基、s-ブチル基、t-ブチル基、ペンチル基、ヘキシル基、デシル基、ラウリル基、ミリスチル基、ステアリル基等の炭素数1~20(好ましくは1~10、特に好ましくは1~3)程度のアルキル基;ビニル基、アリル基、1-ブテニル基、オレイル基、リノレイル基等の炭素数2~20のアルケニル基;エチニル基、プロピニル基等の炭素数2~20のアルキニル基等を挙げることができる。 The monovalent aliphatic hydrocarbon group is preferably an aliphatic hydrocarbon group having 1 to 20 carbon atoms (= C 1-20 ), and examples thereof include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group and an isobutyl group. Carbon number of 1 to 20 (preferably 1 to 10, particularly preferably 1 to 3), such as s-butyl, t-butyl, pentyl, hexyl, decyl, lauryl, myristyl and stearyl groups Alkyl groups; alkenyl groups having 2 to 20 carbon atoms such as vinyl, allyl, 1-butenyl, oleyl and linoleyl; and alkynyls having 2 to 20 carbons such as ethynyl and propynyl. be able to.
 1価の脂環式炭化水素基としては、C3-20脂環式炭化水素基が好ましく、例えば、シクロプロピル基、シクロブチル基、シクロペンチル基、シクロヘキシル基、シクロオクチル基等の3~20員(好ましくは3~15員、特に好ましくは5~8員)程度のシクロアルキル基;シクロペンテニル基、シクロへキセニル基等の3~20員(好ましくは3~15員、特に好ましくは5~8員)程度のシクロアルケニル基;パーヒドロナフタレン-1-イル基、パーヒドロフルオラントレン-3-イル基、パーフルオロデカリン-1-イル基、パーフルオロパーヒドロフェナントレン-1-イル基、ノルボルニル基、アダマンチル基、トリシクロ[5.2.1.02,6]デカン-8-イル基、テトラシクロ[4.4.0.12,5.17,10]ドデカン-3-イル基等の橋かけ環式炭化水素基等を挙げることができる。 As the monovalent alicyclic hydrocarbon group, a C 3-20 alicyclic hydrocarbon group is preferable, and for example, a 3- to 20-membered member such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group or a cyclooctyl group 3 to 15 membered, particularly preferably 5 to 8 membered cycloalkyl group; 3 to 20 membered (preferably 3 to 15 membered, particularly preferably 5 to 8 membered) such as cyclopentenyl group and cyclohexenyl group And the like) perhydronaphthalen-1-yl group, perhydrofluoranthren-3-yl group, perfluorodecalin-1-yl group, perfluoroperhydrophenanthren-1-yl group, norbornyl group, Adamantyl group, tricyclo [5.2.1.0 2,6 ] decan-8-yl group, tetracyclo [4.4.0.1 2,5 . Examples thereof include bridged cyclic hydrocarbon groups such as a [1, 7 10 ] dodecane-3-yl group.
 脂肪族炭化水素基と脂環式炭化水素基とが結合した1価の炭化水素基には、シクロペンチルメチル基、シクロヘキシルメチル基、2-シクロヘキシルエチル基等のシクロアルキル置換アルキル基(例えば、C3-20シクロアルキル置換C1-4アルキル基等)等が含まれる。 Examples of monovalent hydrocarbon groups in which an aliphatic hydrocarbon group and an alicyclic hydrocarbon group are bonded include cycloalkyl substituted alkyl groups such as a cyclopentylmethyl group, a cyclohexylmethyl group and a 2-cyclohexylethyl group (for example, C 3 -20 cycloalkyl substituted C 1-4 alkyl group etc.) and the like.
 R1における1価の炭化水素基としては、とりわけ、1価の飽和脂肪族炭化水素基、1価の飽和脂環式炭化水素基、及びこれらの結合した1価の基が好ましい。 Among the monovalent hydrocarbon groups of R 1 , monovalent saturated aliphatic hydrocarbon groups, monovalent saturated alicyclic hydrocarbon groups, and monovalent radicals having these combined are particularly preferable.
 連結基としては、例えば、カルボニル基(-CO-)、エーテル結合(-O-)、チオエーテル結合(-S-)、エステル結合(-COO-)、アミド結合(-CONH-)、カーボネート結合(-OCOO-)等を挙げることができる。 As a linking group, for example, a carbonyl group (-CO-), an ether bond (-O-), a thioether bond (-S-), an ester bond (-COO-), an amide bond (-CONH-), a carbonate bond ( -OCOO-) etc. can be mentioned.
 ハロゲン原子としては、フッ素原子以外にも、塩素原子、臭素原子、ヨウ素原子が含まれる。 As a halogen atom, in addition to a fluorine atom, a chlorine atom, a bromine atom and an iodine atom are included.
 前記1価の炭化水素基、又は2個以上の炭化水素基が連結基を介して結合した1価の基に結合する水素原子の30%以上は少なくとも1つのフッ素原子を含むハロゲン原子で置換されており、なかでも、50%以上(特に好ましくは80%以上、とりわけ好ましくは90%以上)が少なくとも1つのフッ素原子を含むハロゲン原子で置換されていることが好ましい。尚、上限は100%である。 30% or more of the hydrogen atoms bonded to the monovalent hydrocarbon group or the monovalent group bonded to two or more hydrocarbon groups via a linking group are substituted with a halogen atom containing at least one fluorine atom Among them, it is preferable that at least 50% (particularly preferably at least 80%, particularly preferably at least 90%) is substituted by at least one halogen atom containing fluorine atom. The upper limit is 100%.
 nは1~3の整数であり、Xがハロゲン原子、水素原子、又は水酸基である場合、好ましくはn=1である。また、Xが窒素原子である場合、好ましくはn=2又は3である。 N is an integer of 1 to 3, and when X is a halogen atom, a hydrogen atom or a hydroxyl group, preferably n = 1. In addition, when X is a nitrogen atom, preferably n is 2 or 3.
 化合物(A)の具体例としては、パーフルオロアルカン(直鎖状及び分岐鎖状のパーフルオロアルカンを含む)、パーフルオロシクロアルカン(単環、及び多環のパーフルオロシクロアルカンを含む)、パーフルオロエーテル、パーフルオロポリエーテル、パーフルオロアミン、及びこれらの誘導体(=これらの化合物が有するフッ素原子の少なくとも1つがフッ素原子以外のハロゲン原子、水素原子、及び水酸基から選択される少なくとも1種で置換された化合物であって、少なくとも1つのフッ素原子を有する化合物)等が挙げられる。 Specific examples of the compound (A) include perfluoroalkanes (including linear and branched perfluoroalkanes), perfluorocycloalkanes (including monocyclic and polycyclic perfluorocycloalkanes), per Fluoroether, perfluoropolyether, perfluoroamine, and derivatives thereof (= at least one of the fluorine atoms of these compounds is substituted by at least one selected from a halogen atom other than a fluorine atom, a hydrogen atom, and a hydroxyl group Compounds having at least one fluorine atom) and the like.
 前記パーフルオロアルカンとしては、例えば、パーフルオロメタン、パーフルオロエタン、パーフルオロブタン、パーフルオロイソブタン、パーフルオロイソプロパン等が挙げられる。 Examples of the perfluoroalkane include perfluoromethane, perfluoroethane, perfluorobutane, perfluoroisobutane, perfluoroisopropane and the like.
 前記パーフルオロアルカンのフッ素原子の少なくとも1つが他のハロゲン原子、水素原子、及び水酸基から選択される少なくとも1種で置換された化合物としては、例えば、フレオン12(=ジクロロジフルオロメタン)、フレオン22(=クロロジフルオロメタン)、フレオン113(=1,1,2-トリフルオロトリクロロエタン)、C613H、C817H、C8162、C1021H、C613Br、C817Br、C816Br2、C613CBr2CH2Br、C613CH=CHC613(沸点195℃)、C817CH=CHC817等が挙げられる。 Examples of the compound in which at least one of the fluorine atoms of the perfluoroalkane is substituted with at least one selected from other halogen atoms, hydrogen atoms, and hydroxyl groups include, for example, Freon 12 (= dichlorodifluoromethane), Freon 22 ( = Chlorodifluoromethane), freon 113 (= 1,1,2-trifluorotrichloroethane), C 6 F 13 H, C 8 F 17 H, C 8 F 16 H 2 , C 10 F 21 H, C 6 F 13 Br, C 8 F 17 Br, C 8 F 16 Br 2 , C 6 F 13 CBr 2 CH 2 Br, C 6 F 13 CH = CHC 6 H 13 (boiling point 195 ° C.), C 8 F 17 CH = CHC 8 H 17 mag.
 前記パーフルオロシクロアルカンとしては、例えば、パーフルオロデカリン、パーフルオロメチルデカリン、パーフルオロジメチルデカリン、パーフルオロイソプロピルデカリン、パーフルオロ-n-ブチルデカリン、パーフルオロメチルアダマンタン、パーフルオロジメチルアダマンタン、パーフルオロメチルトリメチルビシクロ[3.3.1]ノナン、パーフルオロジメチルビシクロ[3.3.1]ノナン、パーフルオロトリメチルビシクロ[3.3.1]ノナン、パーフルオロパーヒドロフェナントレン(沸点215℃)、パーフルオロパーヒドロフルオランテン(沸点240℃)、パーフルオロパーヒドロフルオレン(沸点194℃)、パーフルオロジイソプロピルデカリン、パーフルオロ-n-ブチルデカリン、パーフルオロジキシリルメタン、パーフルオロジキシリルエタン、パーフルオロパーヒドロフェナントレン(商品名「APF-215TM」(沸点215℃)、「APF-240TM」(沸点216℃)、「APF-260TM」(沸点260℃)、以上Air Products社製、USA))等が挙げられる。 Examples of the perfluorocycloalkane include perfluorodecalin, perfluoromethyldecalin, perfluorodimethyldecalin, perfluoroisopropyldecalin, perfluoro-n-butyldecalin, perfluoromethyladamantane, perfluorodimethyladamantane, perfluoromethylmethyl. Trimethylbicyclo [3.3.1] nonane, perfluorodimethylbicyclo [3.3.1] nonane, perfluorotrimethylbicyclo [3.3.1] nonane, perfluoroperhydrophenanthrene (boiling point 215 ° C.), perfluoro fluorocarbon Perhydrofluoranthene (boiling point 240 ° C.), perfluoroperhydrofluorene (boiling point 194 ° C.), perfluorodiisopropyldecalin, perfluoro-n-butyldecalin, perfluorodisilane Silylmethane, perfluorodixylethane, perfluoroperhydrophenanthrene (trade name "APF-215TM" (boiling point 215 ° C), "APF-240TM" (boiling point 216 ° C), "APF-260TM" (boiling point 260 ° C), or more Air Products (USA)) and the like.
 前記パーフルオロアルカンのフッ素原子の少なくとも1つが他のハロゲン原子、水素原子、及び水酸基から選択される少なくとも1種で置換された化合物としては、例えば、1-ブロモ-4-パーフルオロイソプロピルシクロヘキサン等が挙げられる。 As a compound in which at least one of the fluorine atoms of the perfluoroalkane is substituted by at least one selected from other halogen atoms, hydrogen atoms, and hydroxyl groups, for example, 1-bromo-4-perfluoroisopropylcyclohexane etc. It can be mentioned.
 前記パーフルオロエーテルとしては、例えば、(CF32CFO(CF24F、(CF32CFO(CF26F、[CF3(CF2u2O、(u=3、5、又は7)等が挙げられる。 Examples of the perfluoroether include (CF 3 ) 2 CFO (CF 2 ) 4 F, (CF 3 ) 2 CFO (CF 2 ) 6 F, [CF 3 (CF 2 ) u ] 2 O, (u = 3, 5, or 7).
 前記パーフルオロポリエーテルとしては、例えば、(CF32CFO(CF24OCF(CF32、(CF32CFO(CF26OCF(CF32、CF3(OCF2CF2p(OCF2qCF3(p/q=0.6~0.7)、CF3(OC(CF3))sF(s=2以上の整数)、(CF32CF(OCF2tF(t=2以上の整数)等が挙げられる。 Examples of the perfluoropolyether include (CF 3 ) 2 CFO (CF 2 ) 4 OCF (CF 3 ) 2 , (CF 3 ) 2 CFO (CF 2 ) 6 OCF (CF 3 ) 2 , CF 3 (OCF) 2 CF 2 ) p (OCF 2 ) q CF 3 (p / q = 0.6 to 0.7), CF 3 (OC (CF 3 )) s F (integer of 2 or more), (CF 3 ) 2 CF (OCF 2 ) t F (t is an integer of 2 or more) or the like.
 前記パーフルオロポリエーテルのフッ素原子の少なくとも1つが他のハロゲン原子、水素原子、及び水酸基から選択される少なくとも1種で置換された化合物としては、例えば、CF3O(CF2CF2O)vCF2CH2OH(v=2、又は3)、F[CF(CF3)CF2O]2CHFCF3等が挙げられる。 As a compound in which at least one of the fluorine atoms of the perfluoropolyether is substituted with at least one selected from other halogen atoms, hydrogen atoms, and hydroxyl groups, for example, CF 3 O (CF 2 CF 2 O) v Examples include CF 2 CH 2 OH (v = 2 or 3), F [CF (CF 3 ) CF 2 O] 2 CHFCF 3 and the like.
 前記パーフルオロアミンとしては、例えば、N(C373、N(C493(沸点178℃)、N(C5113、パーフルオロ-N-メチルパーヒドロキノリン、パーフルオロ-N-メチルパーヒドロイソキノリン等が挙げられる。 Examples of the perfluoroamines include N (C 3 F 7 ) 3 , N (C 4 F 9 ) 3 (boiling point 178 ° C.), N (C 5 F 11 ) 3 and perfluoro-N-methylperhydroquinoline. And perfluoro-N-methylperhydroisoquinoline and the like.
 化合物(A)の分子量は、例えば50~10000、好ましくは100~8000、特に好ましくは500~8000、最も好ましくは1000~7000である。 The molecular weight of the compound (A) is, for example, 50 to 10000, preferably 100 to 8000, particularly preferably 500 to 8000, and most preferably 1000 to 7000.
 化合物(A)の常圧下における沸点は、例えば140℃以上、好ましくは200℃以上(例えば、200~300℃)であることが、室温において揮発し難く、外用薬の形での使用に適する点で好ましい。 The compound (A) has a boiling point of, for example, 140 ° C. or more, preferably 200 ° C. or more (eg, 200 to 300 ° C.) at normal pressure, which is less volatile at room temperature and suitable for use in the form of external preparations Preferred.
 化合物(A)の速やかな蒸散が求められる用途においては、沸点のより低いものを使用することができる。 In applications where rapid evaporation of compound (A) is required, lower boiling point can be used.
 化合物(A)としては、なかでも、パーフルオロアルカン、パーフルオロシクロアルカン、パーフルオロエーテル、パーフルオロポリエーテル、及びパーフルオロアミンから選択される少なくとも1種を使用することが使用感触、撥水性、及び撥油性に優れる点で好ましく、特にパーフルオロポリエーテルを使用することが好ましく、とりわけ、分子量が500~8000(最も好ましくは1000~7000)のパーフルオロポリエーテルを使用することが好ましい。 Among the compounds (A), at least one selected from perfluoroalkanes, perfluorocycloalkanes, perfluoroethers, perfluoropolyethers, and perfluoroamines, among others, feel in use, water repellency, And the use of perfluoropolyethers is particularly preferred, and perfluoropolyethers having a molecular weight of 500 to 8000 (most preferably 1000 to 7000) are particularly preferred.
 (化合物(B))
 本発明における化合物(B)は、下記式(b)で表される、パーフルオロアルキル鎖部と炭化水素鎖部とを有する化合物であり、界面活性能を有する化合物(すなわち、界面活性剤)である。本発明における化合物(B)は上記化合物(A)のゲル化剤として使用される。
Figure JPOXMLDOC01-appb-C000006
(式中、m1、m2は、同一又は異なって、3~22の整数を示す。Yは水素原子又は水酸基を示す)
(Compound (B))
The compound (B) in the present invention is a compound represented by the following formula (b) and having a perfluoroalkyl chain moiety and a hydrocarbon chain moiety, and is a compound having a surface activity ability (ie, a surfactant). is there. The compound (B) in the present invention is used as a gelling agent for the above compound (A).
Figure JPOXMLDOC01-appb-C000006
(Wherein, m1 and m2 are the same or different and each represents an integer of 3 to 22. Y represents a hydrogen atom or a hydroxyl group)
 式(b)中のm1は3~22の整数を示す。本発明においては、なかでも、ゲル化能と溶解性の点で、好ましくは5~18の整数、特に好ましくは7~15の整数である。 M1 in the formula (b) represents an integer of 3 to 22. In the present invention, among them, in view of gelling ability and solubility, it is preferably an integer of 5 to 18, particularly preferably an integer of 7 to 15.
 式(b)中のm2は3~22の整数を示す。本発明においては、なかでも、ゲル化能と溶解性の点で、好ましくは5~18の整数、特に好ましくは6~15の整数である。 M2 in the formula (b) represents an integer of 3 to 22. In the present invention, among them, in view of gelling ability and solubility, it is preferably an integer of 5 to 18, particularly preferably an integer of 6 to 15.
 また、式(b)中のm1+m2は、例えば10~40の整数、好ましくは12~35の整数、特に好ましくは15~30の整数である。 In the formula (b), m1 + m2 is, for example, an integer of 10 to 40, preferably an integer of 12 to 35, and particularly preferably an integer of 15 to 30.
 Yが水酸基の場合の化合物(B)の具体例としては、12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,21,21,21-ヘンイコサフルオロヘンイコサン-1-オール、11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,20-ヘンイコサフルオロイコサン-1-オール、8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,17,17,17-ヘンイコサフルオロヘプタデカン-1-オール、9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,20-ペンタコサフルオロイコサン-1-オール、12,12,13,13,14,14,15,15,16,16,17,17,17-トリデカフルオロヘプタデカン-1-オール、8,8,9,9,10,10,11,11,12,12,13,13,13-トリデカフルオロトリデカン-1-オール、13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,21,21,22,22,23,23,24,24,24-ペンタコサフルオロテトラコサン-1-オール等が挙げられる。 Specific examples of the compound (B) in the case where Y is a hydroxyl group are 12, 12, 13, 13, 14, 14, 15, 15, 16, 16, 17, 17, 18, 18, 19, 19, 20, 20, 21, 21, 21 1 -Henicosa fluorohenicosan -1-ol, 11, 11, 12, 12, 13, 13, 14, 14, 15, 15, 16, 16, 17, 17, 18, 18, 19, 19, 20, 20, 20-henicosafluoroicosan-1-ol, 8, 8, 9, 9, 10, 10, 11, 11, 12, 12, 13, 13, 14, 14 , 15, 15, 16, 16, 17, 17, 17-17-Henichosa fluoroheptadecane-1-ol, 9, 9, 10, 10, 11, 11, 12, 12, 13, 13, 14, 14, 15, 15, 16, 16, 17, 17, 18, 18, 1 , 19, 20, 20, 20-pentacosafluoroicosane-1-ol, 12, 12, 13, 13, 14, 14, 15, 15, 16, 16, 17, 17, 17-tridecafluoroheptadecane -1-ol, 8, 8, 9, 9, 10, 10, 11, 11, 12, 12, 13, 13, 13-tridecafluorotridecane-1-ol, 13, 13, 14, 14, 15 , 15, 16, 16, 17, 17, 18, 18, 19, 19, 20, 20, 21, 21, 22, 22, 23, 23, 24, 24, 24-pentacosafluorotetracosan-1-ol Etc.
 Yが水素原子の場合の化合物(B)の具体例としては、1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10-ヘンイコサフルオロヘンイコサン、1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10-ヘンイコサフルオロイコサン、1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10-ヘンイコサフルオロヘプタデカン、1,1,1,2,2,3,3,4,4,5,5,6,6-トリデカフルオロヘプタデカン、1,1,1,2,2,3,3,4,4,5,5,6,6-トリデカフルオロトリデカン、1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12-ペンタコサフルオロテトラコサン、1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12-ペンタコサフルオロイコサン等が挙げられる。 Specific examples of the compound (B) when Y is a hydrogen atom are 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8 9, 9, 10, 10-Henicosa fluorohenicosan, 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8 9, 9, 10, 10-Henicosa fluoroicosane, 1, 1, 1, 2, 2, 3, 3, 4, 5, 4, 5, 6, 7, 7, 8, 8, 9,9,10,10-Henicosa fluoroheptadecane, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoroheptadecane, 1,1 1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotridecane, 1,1,1,2,2,3,3,4,4,5,5 , 6, 6, 7, 7, 8, 8, 9, 9, 10, 10, 11, 1 , 12, 12-Pentacosafluorotetracosane, 1, 1, 1, 2, 2, 3, 3, 4, 5, 4, 5, 6, 6, 7, 7, 8, 8, 9, 9, 10 10, 11, 11, 12, 12, 12-pentacosafluoroicosane and the like.
 化合物(B)は上記の通りパーフルオロアルキル鎖部と炭化水素鎖部とを備えた化合物であり、前記パーフルオロアルキル鎖部が化合物(A)と親和性を有する。そのため、化合物(A)中に化合物(B)を添加し、相溶させると、化合物(A)中において化合物(B)はパーフルオロアルキル鎖部を外側にし、炭化水素鎖部を内側にして集合体(例えば、ひも状会合体)を形成することができ、前記集合体が化合物(A)中において網目構造を形成することにより、化合物(A)がゲル化される。また、前記集合体の内部は親水的な環境を有するため、例えば、水溶性の物質を内包することも可能である。 The compound (B) is a compound comprising a perfluoroalkyl chain moiety and a hydrocarbon chain moiety as described above, and the perfluoroalkyl chain moiety has affinity to the compound (A). Therefore, when compound (B) is added to compound (A) and compatibilized, compound (B) is assembled with compound (A) with the perfluoroalkyl chain part on the outside and the hydrocarbon chain part on the inside. It is possible to form a body (for example, a string-like association), and the assembly forms a network in the compound (A), whereby the compound (A) is gelled. In addition, since the inside of the assembly has a hydrophilic environment, it is also possible to enclose, for example, a water-soluble substance.
 また、化合物(B)は、化合物(B)に類似の炭化水素と比べると溶血活性が低く、毒性が低い(J.G.Riess,Adv.Mat.,3:249~251(1991))。そのため、生体適合性に優れ、医薬品、医薬部外品、化粧品の分野において使用することができる。 In addition, Compound (B) has lower hemolytic activity and lower toxicity as compared to hydrocarbons similar to Compound (B) (JG Riess, Adv. Mat., 3: 249-251 (1991)). Therefore, it is excellent in biocompatibility and can be used in the fields of pharmaceuticals, quasi-drugs and cosmetics.
 化合物(B)は、例えば、下記方法等により製造することができるが、この製造方法に制限されるものではない。下記方法では式(1)で表されるヨウ化パーフルオロアルキルを使用しているが、これに代えて、臭化パーフルオロアルキルや塩化パーフルオロアルキルを使用することもできる。尚、下記式中のY、m1、m2は上記に同じ。
Figure JPOXMLDOC01-appb-C000007
The compound (B) can be produced, for example, by the following method and the like, but is not limited to this production method. Although the perfluoroalkyl iodide represented by the formula (1) is used in the following method, it is also possible to use perfluoroalkyl bromide or perfluoroalkyl chloride instead. In the following formulas, Y, m1 and m2 are the same as above.
Figure JPOXMLDOC01-appb-C000007
 上記工程[1]は、式(1)で表されるヨウ化パーフルオロアルキルと式(2)で表される不飽和化合物とを反応(ラジカル反応)させる工程である。上記工程[1]を経て、上記式(3)で表される化合物が得られる。 The above step [1] is a step of reacting (radical reaction) the perfluoroalkyl iodide represented by the formula (1) with the unsaturated compound represented by the formula (2). The compound represented by the said Formula (3) is obtained through the said process [1].
 上記反応は無溶媒でも可能であるが、溶媒の存在下で行うことが、製造操作の容易となる点で好ましい。前記溶媒としては、式(1)で表されるヨウ化パーフルオロアルキルと式(2)で表される不飽和化合物の溶解性に優れ、且つこれらのラジカル反応を阻害しないものであれば特に限定されることがなく、例えば、トルエン等の芳香族炭化水素類;THF等のエーテル類;酢酸ブチル等のエステル類;メチルエチルケトン等のケトン類;プロパノール等のアルコール類などを挙げることができる。これらは1種を単独で、又は2種以上を組み合わせて使用することができる。 The above reaction may be carried out without a solvent, but it is preferable to carry out the reaction in the presence of a solvent in terms of facilitating the production operation. The solvent is particularly limited as long as it is excellent in the solubility of the perfluoroalkyl iodide represented by the formula (1) and the unsaturated compound represented by the formula (2) and does not inhibit these radical reactions. For example, aromatic hydrocarbons such as toluene; ethers such as THF; esters such as butyl acetate; ketones such as methyl ethyl ketone; alcohols such as propanol; and the like. These can be used singly or in combination of two or more.
 前記溶媒の使用量としては、式(1)で表されるヨウ化パーフルオロアルキルと式(2)で表される不飽和化合物の総量に対して、例えば50~300重量%程度、好ましくは100~300重量%である。溶媒の使用量が上記範囲を上回ると反応成分の濃度が低くなり、反応速度が低下する傾向がある。 The amount of the solvent used is, for example, about 50 to 300% by weight, preferably about 100% by weight, based on the total amount of the perfluoroalkyl iodide represented by the formula (1) and the unsaturated compound represented by the formula (2). It is ̃300% by weight. When the amount of the solvent used exceeds the above range, the concentration of the reaction component tends to be low, and the reaction rate tends to be low.
 また、上記反応はラジカル開始剤の存在下で行うことが、反応の進行を促進することができる点で好ましい。ラジカル開始剤としては、例えば、アゾ化合物[例えば、2,2’-アゾビス(イソブチロニトリル)、2,2’-アゾビス(2,4-ジメチルバレロニトリル、アゾビスシアノ吉草酸、2,2’-アゾビス(2-アミジノプロパン)ハイドロクロライド、2,2’-アゾビス(2-アミジノプロパン)アセテート等]、無機過酸化物(例えば、過硫酸カリウム、過硫酸ナトリウム、過硫酸アンモニウム等の過硫酸塩、過酸化水素)、有機過酸化物[例えば、過酸化べンゾイル、ジ-t-ブチルパーオキサイド、クメンヒドロパーオキサイド、ビス(2-エトキシエチル)パーオキシジカーボネート]、及びレドックス触媒等を挙げることができる。これらは1種を単独で、又は2種以上を組み合わせて使用することができる。 Moreover, it is preferable to carry out the above reaction in the presence of a radical initiator in that the progress of the reaction can be promoted. Examples of the radical initiator include, for example, azo compounds [for example, 2,2′-azobis (isobutyronitrile), 2,2′-azobis (2,4-dimethylvaleronitrile, azobiscyanovaleric acid, 2,2′- Azobis (2-amidinopropane) hydrochloride, 2,2′-azobis (2-amidinopropane) acetate, etc.], inorganic peroxides (eg, persulfates such as potassium persulfate, sodium persulfate, ammonium persulfate, etc.) Hydrogen peroxide), organic peroxides [eg, benzoyl peroxide, di-t-butyl peroxide, cumene hydroperoxide, bis (2-ethoxyethyl) peroxydicarbonate], redox catalysts, etc. These can be used alone or in combination of two or more.
 上記反応の雰囲気としては、反応を阻害しない限り特に限定されず、例えば、空気雰囲気、窒素雰囲気、アルゴン雰囲気等の何れであってもよい。 The atmosphere for the reaction is not particularly limited as long as the reaction is not inhibited. For example, any of an air atmosphere, a nitrogen atmosphere, an argon atmosphere and the like may be used.
 反応温度は、使用する溶媒等に応じて適宜調整することができ、例えば60~120℃程度である。また、反応時間は、例えば0.1~20時間程度である。反応終了後は、熟成工程を設けてもよい。熟成工程を設ける場合、熟成温度は例えば60~100℃程度、熟成時間は例えば0.1~5時間程度である。また、反応はバッチ式、セミバッチ式、連続式等の何れの方法でも行うことができる。 The reaction temperature can be appropriately adjusted depending on the solvent used and is, for example, about 60 to 120 ° C. The reaction time is, for example, about 0.1 to 20 hours. After completion of the reaction, an aging step may be provided. When the ripening step is provided, the ripening temperature is, for example, about 60 to 100 ° C., and the ripening time is, for example, about 0.1 to 5 hours. The reaction can be carried out by any method such as batch system, semi-batch system, continuous system and the like.
 反応終了後、得られた反応生成物は、例えば、濾過、濃縮、蒸留、抽出、晶析、吸着、再結晶、カラムクロマトグラフィー等の分離手段や、これらを組み合わせた分離手段により分離精製できる。 After completion of the reaction, the obtained reaction product can be separated and purified by separation means such as filtration, concentration, distillation, extraction, crystallization, adsorption, recrystallization, column chromatography, or a combination of these.
 上記工程[2]は、上記工程[1]を経て得られた式(3)で表される化合物を還元処理に付して、化合物(B)を得る工程である。 The step [2] is a step of subjecting the compound represented by the formula (3) obtained through the above step [1] to a reduction treatment to obtain a compound (B).
 式(3)で表される化合物の還元処理は、周知慣用の方法、例えば、水素化還元剤を用いる還元法等により行うことができる。 The reduction treatment of the compound represented by the formula (3) can be carried out by a well-known and commonly used method, for example, a reduction method using a hydrogenation reducing agent.
 前記水素化還元剤としては、例えば、亜鉛、スズ等の金属;水素化アルミニウム、水素化アルミニウムリチウム、水素化ホウ素ナトリウム、水素化ホウ素リチウム、水素化ジイソブチルアルミニウム、水素化ジブチルスズ、水素化トリブチルスズ、水素化ジフェニルスズ、水素化トリフェニルスズ、水素化ホウ素亜鉛、ジボラン等を挙げることができる。 Examples of the hydrogenation reducing agent include metals such as zinc and tin; aluminum hydride, lithium aluminum hydride, sodium borohydride, lithium borohydride, diisobutylaluminum hydride, dibutyltin hydride, tributyltin hydride, hydrogen Diphenyltin halide, triphenyltin hydride, zinc borohydride, diborane and the like can be mentioned.
 還元処理は、溶媒の存在下で行ってもよく、溶媒としては、例えば、メタノール、エタノール、イソプロパノール等のアルコール類及びその水溶液、ジグリム及びその水溶液、スルホラン、ピリジン、DMSO、THF等を挙げることができる。これらは1種を単独で、又は2種以上を組み合わせて使用することができる。 The reduction treatment may be carried out in the presence of a solvent, and examples of the solvent include alcohols such as methanol, ethanol and isopropanol and their aqueous solutions, diglyme and their aqueous solutions, sulfolane, pyridine, DMSO, THF and the like. it can. These can be used singly or in combination of two or more.
 前記溶媒の使用量としては、式(3)で表される化合物に対して、例えば50~300重量%程度、好ましくは100~300重量%である。溶媒の使用量が上記範囲を上回ると反応成分の濃度が低くなり、反応速度が低下する傾向がある。 The amount of the solvent used is, for example, about 50 to 300% by weight, preferably 100 to 300% by weight, relative to the compound represented by the formula (3). When the amount of the solvent used exceeds the above range, the concentration of the reaction component tends to be low, and the reaction rate tends to be low.
 上記反応の雰囲気としては、反応を阻害しない限り特に限定されず、例えば、空気雰囲気、窒素雰囲気、アルゴン雰囲気等の何れであってもよい。 The atmosphere for the reaction is not particularly limited as long as the reaction is not inhibited. For example, any of an air atmosphere, a nitrogen atmosphere, an argon atmosphere and the like may be used.
 反応温度は、使用する溶媒等に応じて適宜調整することができ、例えば60~100℃程度である。また、反応時間は、例えば0.1~20時間程度である。反応終了後は、熟成工程を設けてもよい。熟成工程を設ける場合、熟成温度は例えば10~40℃程度、熟成時間は例えば0.5~5時間程度である。また、反応はバッチ式、セミバッチ式、連続式等の何れの方法でも行うことができる。 The reaction temperature can be appropriately adjusted depending on the solvent used and is, for example, about 60 to 100 ° C. The reaction time is, for example, about 0.1 to 20 hours. After completion of the reaction, an aging step may be provided. When the aging step is provided, the aging temperature is, for example, about 10 to 40 ° C., and the aging time is, for example, about 0.5 to 5 hours. The reaction can be carried out by any method such as batch system, semi-batch system, continuous system and the like.
 反応終了後、得られた反応生成物は、例えば、濾過、濃縮、蒸留、抽出、晶析、吸着、再結晶、カラムクロマトグラフィー等の分離手段や、これらを組み合わせた分離手段により分離精製できる。 After completion of the reaction, the obtained reaction product can be separated and purified by separation means such as filtration, concentration, distillation, extraction, crystallization, adsorption, recrystallization, column chromatography, or a combination of these.
 (ゲル状組成物の製造方法)
 本発明のゲル状組成物は、式(a)で表される化合物(A)の少なくとも1種と、式(b)で表される化合物(B)の少なくとも1種とを相溶させる工程を経て、簡便に製造することができる。
(Method of producing gel composition)
The gel composition of the present invention comprises the step of compatibilizing at least one of the compound (A) represented by the formula (a) and at least one of the compound (B) represented by the formula (b) It can be manufactured simply.
 化合物(A)と化合物(B)は、例えば、80~200℃(好ましくは100~180℃、特に好ましくは120~160℃)で加熱混合することにより相溶して、相溶物を形成する。また、化合物(A)と化合物(B)の相溶は、化合物(A)と化合物(B)とを予め混合し、その後、加熱して相溶させてもよく、化合物(A)を加熱し、そこに徐々に化合物(B)を添加して相溶させてもよい。更に、加熱時は撹拌処理を行うことが好ましい。必要に応じて脱気処理(例えば、室温における遠心分離による脱気処理)を施してもよい。 The compound (A) and the compound (B) are compatibilized by, for example, heat mixing at 80 to 200 ° C. (preferably 100 to 180 ° C., particularly preferably 120 to 160 ° C.) to form a compatibilized substance . In addition, the compound (A) and the compound (B) may be prepared by mixing the compound (A) and the compound (B) in advance and then heating the compound (A) to make the compound compatible. The compound (B) may be gradually added thereto to be compatible. Furthermore, it is preferable to perform stirring processing at the time of heating. If necessary, a degassing treatment (for example, degassing treatment by centrifugation at room temperature) may be performed.
 加熱に要する時間は、例えば3~60分間程度(好ましくは10~30分間)である。 The time required for heating is, for example, about 3 to 60 minutes (preferably 10 to 30 minutes).
 加熱後は、室温(例えば、1~30℃)以下にまで冷却することが好ましい。冷却は、室温で徐々に冷却してもよいし、氷冷等により急速に冷却してもよい。 After heating, it is preferable to cool to room temperature (eg, 1 to 30 ° C.) or less. The cooling may be gradual cooling at room temperature or may be rapid cooling by ice cooling or the like.
 化合物(B)の使用量としては、化合物(A)100重量部に対して、例えば0.1~33重量部、好ましくは0.5~25重量部、特に好ましくは1~18重量部、最も好ましくは2~11重量部である。また、化合物(A)と化合物(B)の使用量の重量比(前者:後者)は、例えば75:25~99.9:0.1であり、好ましくは80:20~99.5:0.5、特に好ましくは85:15~99:1、最も好ましくは90:10~98:2である。化合物(B)は化合物(A)に対して優れた界面活性能を有するため、極めて少量の使用で化合物(A)をゲル化することができる。化合物(B)の使用量が上記範囲を下回ると温度変化によって低粘度化する等、粘度を安定的に維持することが困難となる場合がある。一方、化合物(B)の使用量が上記範囲を上回っても、更なる効果の向上は見られず、不経済である。 The amount of compound (B) used is, for example, 0.1 to 33 parts by weight, preferably 0.5 to 25 parts by weight, particularly preferably 1 to 18 parts by weight, per 100 parts by weight of compound (A). Preferably, it is 2 to 11 parts by weight. The weight ratio of the amount of compound (A) to compound (B) used (the former: the latter) is, for example, 75:25 to 99.9: 0.1, preferably 80:20 to 99.5: 0. .5, particularly preferably 85:15 to 99: 1, most preferably 90:10 to 98: 2. The compound (B) has excellent surfactant activity with respect to the compound (A), so that the compound (A) can be gelled by using a very small amount. If the amount of the compound (B) used falls below the above range, it may be difficult to stably maintain the viscosity, such as viscosity reduction due to temperature change. On the other hand, even if the amount of compound (B) used exceeds the above range, no further improvement in the effect is observed, which is uneconomical.
 得られる相溶物の構成成分全量における化合物(A)由来の成分の占める割合は75~99.9重量%であり、好ましくは80~99.5重量%、特に好ましくは85~99重量%、最も好ましくは90~98重量%である。 The proportion of the component derived from the compound (A) in the total amount of constituents of the obtained compatible material is 75 to 99.9% by weight, preferably 80 to 99.5% by weight, particularly preferably 85 to 99% by weight. Most preferably, it is 90 to 98% by weight.
 従って、得られる相溶物の構成成分全量における化合物(B)由来の成分の占める割合は0.1~25重量%であり、好ましくは0.5~20重量%、特に好ましくは1~15重量%、最も好ましくは2~10重量%である。 Accordingly, the proportion of the component derived from compound (B) in the total amount of the components of the compatible material is 0.1 to 25% by weight, preferably 0.5 to 20% by weight, particularly preferably 1 to 15% by weight. %, Most preferably 2 to 10% by weight.
 また、本発明のゲル状組成物全量における化合物(A)由来の成分の占める割合は例えば30~99.9重量%、好ましくは50~99.9%、より好ましくは75~99.9%、更に好ましくは80~99.5重量%、特に好ましくは85~99重量%、最も好ましくは90~98重量%である。 In addition, the proportion of the component derived from the compound (A) in the gel composition of the present invention is, for example, 30 to 99.9% by weight, preferably 50 to 99.9%, more preferably 75 to 99.9%. More preferably, it is 80 to 99.5% by weight, particularly preferably 85 to 99% by weight, and most preferably 90 to 98% by weight.
 また、本発明のゲル状組成物全量における化合物(B)由来の成分の占める割合は、例えば0.1~70重量%、好ましくは0.1~50重量%、より好ましくは0.1~25重量%であり、更に好ましくは0.5~20重量%、特に好ましくは1~15重量%、最も好ましくは2~10重量%である。 The proportion of the component derived from compound (B) in the total amount of gel composition of the present invention is, for example, 0.1 to 70% by weight, preferably 0.1 to 50% by weight, more preferably 0.1 to 25%. % By weight, more preferably 0.5 to 20% by weight, particularly preferably 1 to 15% by weight, most preferably 2 to 10% by weight.
 また、本発明のゲル状組成物には、化合物(A)と化合物(B)の相溶物以外にも、本発明の効果を損なわない範囲であれば、必要に応じて他の成分を含有していてもよいが、本発明のゲル状組成物全量における、化合物(A)と化合物(B)の相溶物の占める割合は、例えば、5重量%以上、好ましくは10重量%以上、より好ましくは20重量%以上、更に好ましくは30重量%以上、更に好ましくは40重量%以上、更に好ましくは50重量%以上、更に好ましくは60重量%以上、特に好ましくは70重量%以上、とりわけ好ましくは80重量%以上、最も好ましくは90重量%以上である。尚、上限は100重量%である。すなわち、本発明のゲル状組成物は、化合物(A)と化合物(B)の相溶物のみから成るものであってもよい。 In addition, the gel composition of the present invention may contain other components as needed as long as the effects of the present invention are not impaired, besides the compatibilizer of the compound (A) and the compound (B). The proportion of the compatibilizer of the compound (A) and the compound (B) in the whole gel composition of the present invention is, for example, 5% by weight or more, preferably 10% by weight or more. It is preferably at least 20% by weight, more preferably at least 30% by weight, still more preferably at least 40% by weight, still more preferably at least 50% by weight, still more preferably at least 60% by weight, particularly preferably at least 70% by weight, particularly preferably It is at least 80% by weight, most preferably at least 90% by weight. The upper limit is 100% by weight. That is, the gel composition of the present invention may consist of only the compatibilizer of the compound (A) and the compound (B).
 また、本発明のゲル状組成物が含有しても良い他の成分としては、油性成分、及び水性成分の何れであってもよく、用途に応じて適宜調整することができる。例えば、本発明のゲル状組成物を医薬品、医薬部外品、又は化粧品として使用する場合は、医薬品、医薬部外品、又は化粧品に通常含有される成分を特に制限なく含有することができる。特に、本発明のゲル状組成物を医薬品、医薬部外品、又は化粧品として使用する場合、適切な部位において放出されるような物質(例えば、成長因子、抗生物質、栄養素等の薬剤)を含有していてもよい。 Moreover, as another component which the gel-like composition of this invention may contain, any of an oil-based component and an aqueous component may be sufficient, and it can adjust suitably according to a use. For example, when the gel composition of the present invention is used as a drug, quasi drug or cosmetic product, it can contain, without particular limitation, components usually contained in the drug, quasi drug or cosmetic product. In particular, when the gel composition of the present invention is used as a drug, quasi-drug or cosmetic product, it contains a substance (eg, growth factor, antibiotic, nutrient, etc.) to be released at an appropriate site. It may be done.
 また、本発明のゲル状組成物は化合物(A)以外にも他の油性成分を含有していても良いが、化合物(A)以外の油性成分の含有量(2種以上含有する場合はその総量)はゲル状組成物に含まれる油性成分全量の例えば60重量%以下、好ましくは50重量%以下、より好ましくは40重量%以下、更に好ましくは30重量%以下、特に好ましくは20重量%以下、とりわけ好ましくは10重量%以下、最も好ましくは5重量%以下である。尚、下限は0重量%である。 In addition, the gel composition of the present invention may contain other oily components in addition to the compound (A), but the content of the oily components other than the compound (A) (when two or more kinds are contained, The total amount is, for example, 60% by weight or less, preferably 50% by weight or less, more preferably 40% by weight or less, still more preferably 30% by weight or less, particularly preferably 20% by weight or less of the total amount of oil components contained in the gel composition Particularly preferably, it is at most 10% by weight, most preferably at most 5% by weight. The lower limit is 0% by weight.
 更に、本発明のゲル状組成物は化合物(B)以外の界面活性剤を含有していても良いが、化合物(B)以外の界面活性剤の含有量(2種以上含有する場合はその総量)はゲル状組成物に含まれる界面活性剤全量の例えば40重量%以下、好ましくは30重量%以下、より好ましくは20重量%以下、特に好ましくは10重量%以下、最も好ましくは5重量%以下である。尚、下限は0重量%である。尚、本明細書において界面活性剤とは、油性成分への高親和性官能基と低親和性官能基とを併せて有する化合物である。 Furthermore, the gel composition of the present invention may contain a surfactant other than the compound (B), but the content of the surfactant other than the compound (B) (in the case of containing two or more, the total amount thereof ) Is, for example, 40% by weight or less, preferably 30% by weight or less, more preferably 20% by weight or less, particularly preferably 10% by weight or less, most preferably 5% by weight or less of the total amount of surfactant contained in the gel composition It is. The lower limit is 0% by weight. In the present specification, a surfactant is a compound having a high affinity functional group to an oil component and a low affinity functional group in combination.
 本発明のゲル状組成物は高い粘性を有し、流動性を有さない。25℃における粘度[せん断速度0.5s-1における]は、例えば10Pa・s以上、好ましくは20Pa・s以上である。 The gel composition of the present invention has high viscosity and no flowability. The viscosity at 25 ° C. [at a shear rate of 0.5 s −1 ] is, for example, 10 Pa · s or more, preferably 20 Pa · s or more.
 本発明のゲル状組成物は、優れた界面活性能を有する化合物(B)を含有するため、化合物(A)が透明である場合は透明なゲル状組成物として存在する。従って、本発明のゲル状組成物は美観に優れる。 The gel composition of the present invention contains the compound (B) having an excellent surface activity ability, and therefore, when the compound (A) is transparent, it exists as a transparent gel composition. Therefore, the gel composition of the present invention is excellent in appearance.
 本発明のゲル状組成物は、安定性に優れ、化学的、生物学的に極めて不活性である。また、熱にも安定であり、加熱滅菌処理等を行っても本発明のゲル状組成物に含まれる相溶物、すなわち、化合物(A)と化合物(B)との集合体(例えば、ひも状会合体)は、低分子量化することがなく、高い粘性を維持することができる。そのため、高度な衛生管理が求められる分野においても使用することができる。 The gel composition of the present invention is excellent in stability and extremely inactive chemically and biologically. Further, they are stable to heat, and the compatibilizer contained in the gel-like composition of the present invention even after heat sterilization etc., that is, an aggregate of compound (A) and compound (B) (for example, a string (Like aggregate) can maintain high viscosity without reducing molecular weight. Therefore, it can be used also in the field where high hygiene management is required.
 本発明のゲル状組成物は、ガス(例えば、酸素、二酸化炭素、空気)の溶解性に優れる化合物(A)を高濃度に含有するため、適用部位へ高濃度のガスを送達するための手段として好適に使用することができる。 The gel composition of the present invention contains a high concentration of the compound (A) excellent in the solubility of gas (for example, oxygen, carbon dioxide, air), and therefore means for delivering a high concentration of gas to the application site It can be suitably used as
 その他、本発明のゲル状組成物は、疎水性と疎油性とを兼ね備え、且つガスの透過性に優れる化合物(A)を高濃度に含有する。そのため、本発明のゲル状組成物を塗布、乾燥することにより、ガス(特に、酸素)の透過性を有しつつ、疎水性と疎油性とを兼ね備え保護膜を形成することができる。従って、本発明のゲル状組成物は被膜形成剤としても好適に使用することができる。 In addition, the gel-like composition of the present invention contains a compound (A) which is both hydrophobic and oleophobic and is excellent in gas permeability at a high concentration. Therefore, by applying and drying the gel-like composition of the present invention, it is possible to form a protective film having both hydrophobicity and oleophobicity while having gas (especially oxygen) permeability. Accordingly, the gel composition of the present invention can also be suitably used as a film forming agent.
 さらに、本発明のゲル状組成物は、潤滑特性を有し、滑りを向上させ、摩擦を抑える作用を有する。 Furthermore, the gel-like composition of the present invention has lubricating properties, has an effect of improving sliding and suppressing friction.
 従って、本発明のゲル状組成物は、医薬品、医薬部外品、化粧品、又は潤滑剤として好適に使用することができる。本発明のゲル状組成物を医薬品、医薬部外品、化粧品、又は潤滑剤として使用すれば、高い粘性を有し、流動性を有さないため、使用性若しくは適用性に優れる。 Therefore, the gel composition of the present invention can be suitably used as a medicine, quasi-drug, cosmetics, or lubricant. When the gel composition of the present invention is used as a medicine, quasi-drug, cosmetics, or lubricant, it has high viscosity and does not have fluidity, so it is excellent in usability or applicability.
 本発明のゲル状組成物が医薬品、医薬部外品、又は化粧品である場合、皮膚に直接塗布することにより使用してもよく、皮膚に着装される貼付剤、経皮パッチ、硬膏剤、包帯剤等の支持体に染み込ませて使用してもよい。 When the gel composition of the present invention is a pharmaceutical product, quasi-drug or cosmetic product, it may be used by applying directly to the skin, patch applied to the skin, transdermal patch, plaster, bandage It may be used by impregnating with a support such as an agent.
 特に、本発明のゲル状組成物が医薬品、又は医薬部外品である場合、これを患部に塗布すれば、ガス(特に、酸素)の透過性を保持しつつ、汚染や塵埃から患部を保護することができる被膜を形成することができる。また、本発明のゲル状組成物が化粧品である場合、これを皮膚に塗布すれば、ガス(特に、酸素)の透過性を保持しつつ(すなわち、皮膚呼吸を阻害することなく)、皮膚表面のシミ等を隠し、皮膚表面を均等に整えることができる被膜を形成することができる。 In particular, when the gel composition of the present invention is a pharmaceutical product or quasi-drug product, if it is applied to the affected area, the affected area is protected from contamination and dust while maintaining the permeability of gas (especially oxygen). Can form a coating. In addition, when the gel composition of the present invention is a cosmetic, if it is applied to the skin, while maintaining the permeability of gas (especially oxygen) (that is, without inhibiting skin respiration), the skin surface And the like can be concealed to form a film capable of evenly conditioning the skin surface.
 以下、実施例に基づいて本発明をより詳細に説明するが、本発明はこれらの実施例により限定されるものではない。 EXAMPLES The present invention will be described in more detail based on examples given below, but the invention is not meant to be limited by these examples.
 調製例1[ゲル化剤(1):12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,21,21,21-ヘンイコサフルオロヘンイコサン-1-オールの合成]
[工程1]
 100mLのナスフラスコにパーフルオロデシルヨージド9.680g(15mmol)、10-ウンデセン-1-オール5.123g(30.1mmol)、及び脱水トルエン5mLを加え、導入管を通じて、アルゴンガス気流下、90℃で撹拌した。
 反応混合液に2,2’-アゾビス(イソブチロニトリル)20mg程度を約30~45分おきに8回程度、1H-NMRおよびGC/MSを用いてパーフルオロデシルヨージドの反応の完結を確認するまで加えた。
 反応完結後、反応混合液にトルエン(30mL)を追加し、80℃で30分撹拌した。室温で静置して一日程度かけて室温まで放冷し、析出した白色固体をろ過して分取し、再度トルエン(30mL)を加え、1H-NMRで10-ウンデセン-1-オールの二重結合由来のピークが消失するまで上記の操作を繰り返した(計3回)。
 得られた白色残渣を乾燥して、12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,21,21,21-ヘンイコサフルオロ-10-ヨードヘンイコサン-1-オール7.631g(9.35mmol、収率62%)を得た。
Preparation Example 1 [gelling Agent (1): 12, 12, 13, 13, 14, 14, 15, 15, 16, 16, 17, 17, 18, 18, 19, 19, 20, 20, 21, 21] Synthesis of 1,21-Henicosa fluorohenicosan-1-ol]
[Step 1]
In a 100 mL eggplant flask, 9.680 g (15 mmol) of perfluorodecyl iodide, 5.123 g (30.1 mmol) of 10-undecen-1-ol, and 5 mL of dehydrated toluene are added, and 90 is introduced through an inlet tube under argon gas flow. Stir at ° C.
About 20 mg of 2,2'-azobis (isobutyronitrile) in the reaction mixture about 8 times every about 30 to 45 minutes, using 1 H-NMR and GC / MS to complete the reaction of perfluorodecyl iodide Was added until confirmed.
After completion of the reaction, toluene (30 mL) was added to the reaction mixture and stirred at 80 ° C. for 30 minutes. The mixture is allowed to stand at room temperature and allowed to cool to room temperature over the course of a day, and the precipitated white solid is filtered and separated, toluene (30 mL) is added again, and 10-undecen-1-ol is obtained by 1 H-NMR. The above operation was repeated until the peak derived from double bond disappeared (total 3 times).
The obtained white residue is dried, and 12, 12, 13, 13, 14, 14, 15, 15, 16, 16, 17, 17, 18, 18, 19, 19, 20, 20, 21, 21, 21 There were obtained 7.631 g (9.35 mmol, yield 62%) of 21-henicosfluoro-10-iodohenicosan-1-ol.
[工程2]
 300mLのナスフラスコに上記12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,21,21,21-ヘンイコサフルオロ-10-ヨードヘンイコサン-1-オール7.030g(8.6mmol)、及びエタノールを加え、導入管を用いて、導入側は濃塩酸にアルゴンガスをバブリングさせたフラスコに通し、排気側はアルカリトラップに通し、80℃のオイルバス中で激しく撹拌した。
 反応混合物に粉末亜鉛を6回に分けて0.3gずつ加えた。オイルバスにて40℃で加熱し、アルゴンガスのバブリングを停止した。反応混合物にイソプロピルエーテル(100mL)と脱イオン水(100mL)を加えて30分激しく撹拌し、その後室温で静置した。有機層を分液ロートに移し、飽和炭酸水素ナトリウム水(50mL)、飽和食塩水(30mL)で洗浄(各2回)し、有機層を乾燥剤(無水硫酸マグネシウム)で15分乾燥した。
 乾燥剤をろ別し、エバポレーターで濃縮し、トルエン(100mL)に加熱溶解し、撹拌しながら室温で放冷した。析出した白色沈殿を吸引ろ過により分取し、エバポレーターで乾燥し、下記式(b-1)で表される、白色固体状のゲル化剤(1)(12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,21,21,21-ヘンイコサフルオロヘンイコサン-1-オール)4.83g(7.0mmol、収率82%)を得た。反応生成物の構造は1H-NMRにより確認した。
1H-NMR(400MHz,CDCl3):δ=3.65(t,2H),2.05(m,2H),1.56(m,4H),1.29(m,14H),1.20(t,1H)
[Step 2]
The above 12,12,13,13,14,14,15,15,16,16,17,17,18,19,19,20,20,21,21,21-Heniko Add 7.030 g (8.6 mmol) of safluoro-10-iodohenicosan-1-ol and ethanol, and introduce it through a flask in which argon gas is bubbled in concentrated hydrochloric acid using an inlet tube, and exhaust The side was passed through an alkali trap and vigorously stirred in an 80 ° C. oil bath.
0.3 g of powdered zinc was added to the reaction mixture in six portions. The mixture was heated at 40 ° C. in an oil bath and bubbling of argon gas was stopped. Isopropyl ether (100 mL) and deionized water (100 mL) were added to the reaction mixture and vigorously stirred for 30 minutes, and then allowed to stand at room temperature. The organic layer was transferred to a separatory funnel, washed with saturated aqueous sodium hydrogen carbonate solution (50 mL) and saturated brine (30 mL) (twice each), and the organic layer was dried with a desiccant (anhydrous magnesium sulfate) for 15 minutes.
The drying agent was filtered off, concentrated by an evaporator, dissolved by heating in toluene (100 mL) and allowed to cool at room temperature while stirring. The precipitated white precipitate is separated by suction filtration, dried by an evaporator, and represented by the following formula (b-1), as a white solid gelling agent (1) (12, 12, 13, 13, 14, 14, 15, 15, 16, 16, 17, 17, 18, 18, 19, 19, 20, 20, 21, 21, 21-Henicosa fluorohenicosan-1-ol) 4.83 g (7. 0 mmol, yield 82%) was obtained. The structure of the reaction product was confirmed by 1 H-NMR.
1 H-NMR (400 MHz, CDCl 3 ): δ = 3.65 (t, 2 H), 2.05 (m, 2 H), 1.56 (m, 4 H), 1.29 (m, 14 H), 1.20 (t, 1 H)
Figure JPOXMLDOC01-appb-C000008
Figure JPOXMLDOC01-appb-C000008
 調製例2[ゲル化剤(2):11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,20-ヘンイコサフルオロイコサン-1-オールの合成]
 調製例1の工程1において、10-ウンデセン-1-オールの代わりに9-デセン-1-オールを用いた以外は調製例1と同様にして、下記式(b-2)で表される、ゲル化剤(2)(11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,20-ヘンイコサフルオロイコサン-1-オール)2.284g,3.38mmol,収率94%)を得た。
1H-NMR(400MHz,CDCl3):δ=3.64(t,2H),2.05(m,2H),1.57(m,4H),1.30(m,12H),1.20(t,1H)
Preparation Example 2 [gelling Agent (2): 11, 11, 12, 12, 13, 13, 14, 14, 15, 15, 16, 16, 17, 17, 18, 18, 19, 19, 20, 20] , 20-Synthesis of fluoro icosane-1-ol]
A compound represented by the following formula (b-2) in the same manner as in Preparation Example 1 except that 9-decene-1-ol was used instead of 10-undecen-1-ol in Step 1 of Preparation Example 1. Gelling agent (2) (11, 11, 12, 12, 13, 13, 14, 14, 15, 15, 16, 16, 17, 17, 18, 18, 19, 19, 20, 20, 20-hen Eicosafurolicocosan-1-ol) 2.284 g, 3.38 mmol, 94% yield was obtained.
1 H-NMR (400 MHz, CDCl 3 ): δ = 3.64 (t, 2 H), 2.05 (m, 2 H), 1.57 (m, 4 H), 1.30 (m, 12 H), 1.20 (t, 1 H)
Figure JPOXMLDOC01-appb-C000009
Figure JPOXMLDOC01-appb-C000009
 調製例3[ゲル化剤(3):9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,20-ペンタコサフルオロイコサン-1-オールの合成]
 調製例1の工程1において、パーフルオロデシルヨージドの代わりにパーフルオロドデシルヨージド、10-ウンデセン-1-オールの代わりに7-オクテン-1-オールを用いた以外は調製例1と同様にして、下記式(b-3)で表される、ゲル化剤(3)(9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,17,17,18,18,19,19,20,20,20-ペンタコサフルオロイコサン-1-オール)1.23g,1.65mmol,収率47%)を得た。
1H-NMR(400MHz,CDCl3):δ=3.65(t,2H),2.03(m,2H),1.58(m,4H),1.30(m,8H),1.20(t,1H)
Preparation Example 3 [gelling Agent (3): 9, 9, 10, 10, 11, 11, 12, 12, 13, 13, 14, 14, 15, 15, 16, 16, 17, 17, 18, 18] , 19, 19, 20, 20, 20-Synthesis of pentacosafluoroicosane-1-ol]
The same procedure as in Preparation Example 1 is repeated, except that perfluorododecyl iodide is used in place of perfluorodecyl iodide and 7-octene-1-ol is used in place of 10-undecen-1-ol in Preparation Example 1. And a gelling agent (3) (9, 9, 10, 10, 11, 11, 12, 12, 13, 13, 14, 14, 15, 15, 16) represented by the following formula (b-3) , 16, 17, 17, 18, 18, 19, 19, 20, 20, 20-pentacosafluoroicosan-1-ol) (1.23 g, 1.65 mmol, yield 47%).
1 H-NMR (400 MHz, CDCl 3 ): δ = 3.65 (t, 2 H), 2.03 (m, 2 H), 1.58 (m, 4 H), 1.30 (m, 8 H), 1.20 (t, 1 H)
Figure JPOXMLDOC01-appb-C000010
Figure JPOXMLDOC01-appb-C000010
 調製例4[ゲル化剤(4):1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12-ペンタコサフルオロテトラコサンの合成]
 調製例1の工程1において、パーフルオロデシルヨージドの代わりにパーフルオロドデシルヨージド、10-ウンデセン-1-オールの代わりに1-ドデセンを用いた以外は調製例1と同様にして、下記式(b-4)で表される、ゲル化剤(4)(1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12-ペンタコサフルオロテトラコサン)1.23g,1.65mmol,収率47%)を得た。
1H-NMR(400MHz,CDCl3):δ=2.05(m,2H),1.60(m,2H),1.25-1.42(m,18H),0.88(t,3H)
Preparation Example 4 [gelling agent (4): 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10 Synthesis of 10,11,11,11,12,12-Pentacosafluorotetracosane]
In the same manner as in Preparation Example 1 except that perfluorododecyl iodide was used instead of perfluorodecyl iodide and 1-dodecene instead of 10-undecen-1-ol was used in place of perfluorodecyl iodide in Preparation Example 1; The gelling agent (4) (1, 1, 1, 2, 2, 3, 3, 4, 5, 4, 5, 6, 7, 7, 8, 8) represented by (b-4) , 9, 9, 10, 10, 11, 11, 12, 12-pentacosafluorotetracosane) 1.23 g, 1.65 mmol, yield 47%) was obtained.
1 H-NMR (400 MHz, CDCl 3 ): δ = 2.05 (m, 2 H), 1.60 (m, 2 H), 1.25-1.42 (m, 18 H), 0.88 (t, 3 H)
Figure JPOXMLDOC01-appb-C000011
Figure JPOXMLDOC01-appb-C000011
 調製例5[ゲル化剤(5):1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12-ペンタコサフルオロイコサンの合成]
 調製例1の工程1において、パーフルオロデシルヨージドの代わりにパーフルオロドデシルヨージド、10-ウンデセン-1-オールの代わりに1-オクテンを用いた以外は調製例1と同様にして、下記式(b-5)で表される、ゲル化剤(5)(1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12-ペンタコサフルオロイコサン)2.42g,3.38mmol,収率93%)を得た。
1H-NMR(400MHz,CDCl3):δ=2.05(m,2H),1.60(m,2H),1.25-1.42(m,10H),0.88(t,3H)
Preparation Example 5 [gelling agent (5): 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10 , 10, 11, 11, 12, 12-Synthesis of pentacosafluoroicosane]
In the same manner as in Preparation Example 1 except that perfluorododecyl iodide was used instead of perfluorodecyl iodide and 1-octene instead of 10-undecen-1-ol was used in place of perfluorodecyl iodide in Preparation Example 1; A gelling agent (5) represented by (b-5) (1, 1, 1, 2, 2, 3, 3, 4, 5, 4, 5, 6, 7, 7, 8, 8) , 9, 9, 10, 10, 11, 11, 12, 12-pentacosafluoroicosane) 2.42 g, 3.38 mmol, yield 93%).
1 H-NMR (400 MHz, CDCl 3 ): δ = 2.05 (m, 2 H), 1.60 (m, 2 H), 1.25-1.42 (m, 10 H), 0.88 (t, 3 H)
Figure JPOXMLDOC01-appb-C000012
Figure JPOXMLDOC01-appb-C000012
 実施例1
 ポリパーフルオロメチルイソプロピルエーテル(分子量1500)を試験管に1cm3量りとり、これにゲル化剤(1)を5重量%になるように加えて混合し、150℃で加熱撹拌してこれらを相溶させ、25℃まで冷却して組成物(ポリパーフルオロメチルイソプロピルエーテル(分子量1500)の含有量:95重量%)を得た。
Example 1
1 cm 3 of polyperfluoromethyl isopropyl ether (molecular weight 1500) is added to a test tube, to which 5% by weight of the gelling agent (1) is added and mixed, and heated and stirred at 150 ° C. It was dissolved and cooled to 25 ° C. to obtain a composition (content of polyperfluoromethyl isopropyl ether (molecular weight 1500): 95% by weight).
 実施例2~10、比較例1~6
 下記表1(単位:重量%)に記載の通りに処方を変更した以外は実施例1と同様にして組成物を得た。
Examples 2 to 10, Comparative Examples 1 to 6
A composition was obtained in the same manner as in Example 1 except that the formulation was changed as described in the following Table 1 (unit: wt%).
<ゲル化能評価>
 実施例及び比較例で得られた組成物の外観を目視で観察し、各種流動性有機物質の流動性があるものを「×」、流動性がないものを「○」として評価した。結果を下記表1にまとめて示す。
<Evaluation of gelation ability>
The appearances of the compositions obtained in Examples and Comparative Examples were visually observed, and those having fluidity of various flowable organic substances were evaluated as “x”, and those having no fluidity were evaluated as “o”. The results are summarized in Table 1 below.
Figure JPOXMLDOC01-appb-T000013
Figure JPOXMLDOC01-appb-T000013
 尚、表1中の各成分を以下に説明する。
 ポリパーフルオロメチルイソプロピルエーテル(分子量1500):ソルベイ社製、商品名「フォンブリンHC/04」、沸点:200~270℃
 ポリパーフルオロメチルイソプロピルエーテル(分子量6250):ソルベイ社製、商品名「フォンブリンHC/R」、沸点:200~270℃
 ゲル化剤(1)~(5):調製例1~5で得られたものを使用
 ゲル化剤(6):12-ヒドロキシステアリン酸、伊藤製油(株)製
 ゲル化剤(7):ジベンジリデンソルビトール、新日本理化(株)製、商品名「ゲルオールD」
 ゲル化剤(8):イヌリンステアリン酸エステル、千葉製粉(株)製、商品名「レオパールISL2」
Each component in Table 1 will be described below.
Polyperfluoromethyl isopropyl ether (molecular weight 1500): manufactured by Solvay, trade name "fonbrin HC / 04", boiling point: 200 to 270 ° C
Polyperfluoromethyl isopropyl ether (molecular weight 6250): manufactured by Solvay, trade name "fonbrin HC / R", boiling point: 200 to 270 ° C
Gelling agents (1) to (5): The products obtained in Preparation Examples 1 to 5 are used Gelling agent (6): 12-hydroxystearic acid, manufactured by Ito Oil Co., Ltd. Gelling agent (7): Di Benzylidene sorbitol, manufactured by Shin Nippon Rika Co., Ltd., trade name "Gelall D"
Gelling agent (8): inulin stearic acid ester, manufactured by Chiba Flour Mills Co., Ltd., trade name "Leopard ISL2"
 以上のまとめとして本発明の構成及びそのバリエーションを以下に付記する。
[1] 下記相溶物を含むゲル状組成物。
 相溶物:式(a)で表される化合物(A)と、式(b)で表される化合物(B)との相溶物[若しくは、式(a)で表される化合物(A)と、式(b)で表される化合物(B)を80~200℃で加熱混合して得られる混合物]であって、前記相溶物構成成分全量の75~99.9重量%(好ましくは80~99.5重量%、特に好ましくは85~99重量%、最も好ましくは90~98重量%)が化合物(A)由来の成分である相溶物
[2] 式(a)中のR1が1価の飽和脂肪族炭化水素基、1価の飽和脂環式炭化水素基、及びこれらの2個以上がエーテル結合を介して結合した1価の基であり、R1を構成する炭素原子に結合する水素原子の30%以上は少なくとも1つのフッ素原子を含むハロゲン原子で置換されている基である、[1]に記載のゲル状組成物。
[3] 化合物(A)が、パーフルオロアルカン、パーフルオロシクロアルカン、パーフルオロエーテル、パーフルオロポリエーテル、パーフルオロアミン、及びこれらの化合物が有するフッ素原子の少なくとも1つがフッ素原子以外のハロゲン原子、水素原子、及び水酸基から選択される少なくとも1種で置換された化合物であって、少なくとも1つのフッ素原子を有する化合物、から選択される少なくとも1種の化合物である、[1]に記載のゲル状組成物。
[4] 化合物(A)が、パーフルオロアルカン、パーフルオロシクロアルカン、パーフルオロエーテル、パーフルオロポリエーテル、及びパーフルオロアミンから選択される少なくとも1種である、[1]に記載のゲル状組成物。
[5] 化合物(A)がパーフルオロポリエーテルである、[1]に記載のゲル状組成物。
[6] 化合物(A)の分子量が1000~10000(好ましくは1000~8000、特に好ましくは1000~7000)である、[1]~[5]の何れか1つに記載のゲル状組成物。
[7] 化合物(A)の常圧下における沸点が140~300℃(好ましくは200~300℃)である、[1]~[6]の何れか1つに記載のゲル状組成物。
[8] 化合物(B)が式(b)で表され、式(b)中のm1が7~15の整数、m2が5~15の整数、m1+m2が15~30の整数である化合物である、[1]~[7]の何れか1つに記載のゲル状組成物。
[9] 化合物(B)が、式(b-1)、(b-2)、(b-3)、(b-4)、及び(b-5)で表される化合物から選択される少なくとも1種である、[1]~[7]の何れか1つに記載のゲル状組成物。
[10] 相溶物構成成分全量の0.1~25重量%(好ましくは0.5~20重量%、特に好ましくは1~15重量%、最も好ましくは2~10重量%)が化合物(B)由来の成分である、[1]~[9]の何れか1つに記載のゲル状組成物。
[11] ゲル状組成物全量における化合物(A)と化合物(B)の相溶物の占める割合が5~100重量%(下限は、好ましくは10重量%、より好ましくは20重量%、更に好ましくは30重量%、更に好ましくは40重量%、更に好ましくは50重量%、更に好ましくは60重量%、特に好ましくは70重量%、とりわけ好ましくは80重量%、最も好ましくは90重量%)である、[1]~[10]の何れか1つに記載のゲル状組成物。
[12] ゲル状組成物に含まれる油性成分全量における化合物(A)の占める割合が40重量%以上(好ましくは50重量%以上、より好ましくは60重量%以上、更に好ましくは70重量%以上、特に好ましくは80重量%以上、とりわけ好ましくは90重量%以上、最も好ましくは95重量%以上)である、[1]~[11]の何れか1つに記載のゲル状組成物。
[13] ゲル状組成物に含まれる、油性成分への高親和性官能基と水性成分への高親和性官能基とを併せて有する化合物全量における化合物(B)の占める割合が40重量%以上(好ましくは50重量%以上、より好ましくは60重量%以上、更に好ましくは70重量%以上、特に好ましくは80重量%以上、とりわけ好ましくは90重量%以上、最も好ましくは95重量%以上)である、[1]~[12]の何れか1つに記載のゲル状組成物。
[14] 25℃、せん断速度0.5s-1における粘度が10Pa・s以上(好ましくは20Pa・s以上)である、[1]~[13]の何れか1つに記載のゲル状組成物。
[15] 医薬品、医薬部外品、化粧品、又は潤滑剤である、[1]~[14]の何れか1つに記載のゲル状組成物。
[16] [1]~[14]の何れか1つに記載のゲル状組成物の医薬品、医薬部外品、化粧品、又は潤滑剤としての使用。
[17] 被膜形成剤である、[1]~[15]の何れか1つに記載のゲル状組成物
[18] [1]~[15]の何れか1つに記載のゲル状組成物の被膜形成剤としての使用。
As a summary of the above, the configuration of the present invention and variations thereof will be additionally described below.
[1] A gel-like composition containing the following compatible substance:
Compatibilizer: compatibilizer of the compound (A) represented by the formula (a) and the compound (B) represented by the formula (b) [or the compound (A) represented by the formula (a) And a mixture obtained by heating and mixing the compound (B) represented by the formula (b) at 80 to 200 ° C.], which is 75 to 99.9% by weight of the total amount of the components of the compatible substance (preferably 80 to 99.5% by weight, particularly preferably 85 to 99% by weight, most preferably 90 to 98% by weight) is a component derived from compound (A) [2] compatible substance [R 1 in formula (a) Is a monovalent saturated aliphatic hydrocarbon group, a monovalent saturated alicyclic hydrocarbon group, and a monovalent group in which two or more of these are bonded via an ether bond, and a carbon atom constituting R 1 30% or more of the hydrogen atoms bonded to are groups substituted with a halogen atom containing at least one fluorine atom [1 The gel composition according to.
[3] The compound (A) is a perfluoroalkane, a perfluorocycloalkane, a perfluoroether, a perfluoropolyether, a perfluoroamine, and a halogen atom in which at least one of the fluorine atoms of these compounds is other than a fluorine atom, The gel-like compound according to [1], which is a compound substituted with at least one selected from a hydrogen atom and a hydroxyl group, and having at least one fluorine atom. Composition.
[4] The gel composition according to [1], wherein the compound (A) is at least one selected from perfluoroalkanes, perfluorocycloalkanes, perfluoroethers, perfluoropolyethers, and perfluoroamines. object.
[5] The gel composition according to [1], wherein the compound (A) is a perfluoropolyether.
[6] The gel composition according to any one of [1] to [5], wherein the molecular weight of the compound (A) is 1000 to 10000 (preferably 1000 to 8000, particularly preferably 1000 to 7000).
[7] The gel composition according to any one of [1] to [6], which has a boiling point of 140 to 300 ° C. (preferably 200 to 300 ° C.) under normal pressure of the compound (A).
[8] a compound wherein the compound (B) is represented by the formula (b), m1 in the formula (b) is an integer of 7 to 15, m2 is an integer of 5 to 15, and m1 + m2 is an integer of 15 to 30 The gel composition according to any one of [1] to [7].
[9] The compound (B) is at least one selected from the compounds represented by formulas (b-1), (b-2), (b-3), (b-4) and (b-5) The gel composition according to any one of [1] to [7], which is one type.
[10] 0.1 to 25% by weight (preferably 0.5 to 20% by weight, particularly preferably 1 to 15% by weight, most preferably 2 to 10% by weight) of the total amount of the components of the compatibilizing agent is the compound (B The gel composition according to any one of [1] to [9], which is a component derived from the above.
[11] The proportion of the compatibilizer of compound (A) and compound (B) in the total amount of gel-like composition is 5 to 100% by weight (the lower limit is preferably 10% by weight, more preferably 20% by weight, further preferably) Is 30% by weight, more preferably 40% by weight, more preferably 50% by weight, more preferably 60% by weight, particularly preferably 70% by weight, particularly preferably 80% by weight, most preferably 90% by weight) The gel composition according to any one of [1] to [10].
[12] The proportion of the compound (A) in the total amount of oily components contained in the gel-like composition is 40% by weight or more (preferably 50% by weight or more, more preferably 60% by weight or more, still more preferably 70% by weight or more) The gel composition according to any one of [1] to [11], which is particularly preferably at least 80% by weight, particularly preferably at least 90% by weight, most preferably at least 95% by weight.
[13] The proportion of the compound (B) in the total amount of compounds having a high affinity functional group to an oily component and a high affinity functional group to an aqueous component contained in the gel-like composition is 40% by weight or more (Preferably 50 wt% or more, more preferably 60 wt% or more, still more preferably 70 wt% or more, particularly preferably 80 wt% or more, particularly preferably 90 wt% or more, most preferably 95 wt% or more) The gel composition according to any one of [1] to [12].
[14] The gel composition according to any one of [1] to [13], which has a viscosity of 10 Pa · s or more (preferably 20 Pa · s or more) at 25 ° C. and a shear rate of 0.5 s −1 . .
[15] The gel composition according to any one of [1] to [14], which is a medicine, quasi-drug, cosmetics, or a lubricant.
[16] Use of the gel composition according to any one of [1] to [14] as a medicine, quasi-drug, cosmetics, or lubricant.
[17] The gel composition according to any one of [1] to [15], which is a film forming agent [18] The gel composition according to any one of [1] to [15] Use as a film forming agent.
 本発明のゲル状組成物は、高い粘性を有し、流動性を有さない。また、安定性に優れ、化学的、生物学的に極めて不活性である。更に、ガスの溶解性や透過性に優れる。更にまた、本発明のゲル状組成物は熱に安定であり、加熱滅菌処理等を行っても粘性を高く維持することができる。そのため、医薬品、医薬部外品、化粧品、又は潤滑剤等として好適に使用することができる。 The gel composition of the present invention has high viscosity and no flowability. In addition, they are excellent in stability and extremely inactive chemically and biologically. Furthermore, the solubility and permeability of the gas are excellent. Furthermore, the gel composition of the present invention is stable to heat, and can maintain its viscosity high even after heat sterilization and the like. Therefore, it can be suitably used as pharmaceuticals, quasi-drugs, cosmetics, lubricants and the like.

Claims (4)

  1.  下記相溶物を含むゲル状組成物。
     相溶物:下記式(a)
    Figure JPOXMLDOC01-appb-C000001
    (式中、R1は1価の炭化水素基、又は2個以上の炭化水素基が連結基を介して結合した1価の基を示し、R1を構成する炭素原子に結合する水素原子の30%以上は少なくとも1つのフッ素原子を含むハロゲン原子で置換されている。Xはハロゲン原子、水素原子、窒素原子、又は水酸基を示し、nは1~3の整数を示す)
    で表される化合物(A)と、下記式(b)
    Figure JPOXMLDOC01-appb-C000002
    (式中、m1、m2は、同一又は異なって、3~22の整数を示す。Yは水素原子又は水酸基を示す)
    で表される化合物(B)との相溶物であって、前記相溶物構成成分全量の75~99.9重量%が化合物(A)由来の成分である相溶物
    The gel-like composition containing the following compatibles.
    Compatibilizer: the following formula (a)
    Figure JPOXMLDOC01-appb-C000001
    (Wherein, R 1 represents a monovalent hydrocarbon group or a monovalent group in which two or more hydrocarbon groups are linked via a linking group, and a hydrogen atom of a hydrogen atom bonded to a carbon atom constituting R 1 30% or more is substituted by a halogen atom containing at least one fluorine atom, X is a halogen atom, a hydrogen atom, a nitrogen atom, or a hydroxyl group, and n is an integer of 1 to 3)
    And a compound (A) represented by the following formula (b)
    Figure JPOXMLDOC01-appb-C000002
    (Wherein, m1 and m2 are the same or different and each represents an integer of 3 to 22. Y represents a hydrogen atom or a hydroxyl group)
    Compatibilized with the compound (B), wherein 75 to 99.9% by weight of the total of the compatibilizer components is a component derived from the compound (A)
  2.  化合物(A)が、パーフルオロアルカン、パーフルオロシクロアルカン、パーフルオロエーテル、パーフルオロポリエーテル、パーフルオロアミン、及びこれらの化合物が有するフッ素原子の少なくとも1つがフッ素原子以外のハロゲン原子、水素原子、及び水酸基から選択される少なくとも1種で置換された化合物であって、少なくとも1つのフッ素原子を有する化合物、から選択される少なくとも1種の化合物である、請求項1に記載のゲル状組成物。 The compound (A) is a perfluoroalkane, a perfluorocycloalkane, a perfluoroether, a perfluoropolyether, a perfluoroamine, and at least one of the fluorine atoms of these compounds is a halogen atom other than a fluorine atom, a hydrogen atom, The gel composition according to claim 1, wherein the gel composition is a compound substituted with at least one selected from the group consisting of: and a hydroxyl group, and a compound having at least one fluorine atom.
  3.  医薬品、医薬部外品、化粧品、又は潤滑剤である、請求項1又は2に記載のゲル状組成物。 The gel composition according to claim 1 or 2, which is a medicine, quasi-drug, cosmetics, or a lubricant.
  4.  被膜形成剤である、請求項1~3の何れか1項に記載のゲル状組成物。 The gel composition according to any one of claims 1 to 3, which is a film forming agent.
PCT/JP2018/026517 2017-07-21 2018-07-13 Gelled composition WO2019017295A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019531011A JP6878724B2 (en) 2017-07-21 2018-07-13 Gel-like composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017142253 2017-07-21
JP2017-142253 2017-07-21

Publications (1)

Publication Number Publication Date
WO2019017295A1 true WO2019017295A1 (en) 2019-01-24

Family

ID=65015656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/026517 WO2019017295A1 (en) 2017-07-21 2018-07-13 Gelled composition

Country Status (2)

Country Link
JP (1) JP6878724B2 (en)
WO (1) WO2019017295A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11509843A (en) * 1995-07-24 1999-08-31 アライアンス ファーマシューティカル コーポレイション Reverse gel consisting of continuous fluorinated phase
JP2004075540A (en) * 2002-08-09 2004-03-11 Rohto Pharmaceut Co Ltd Gel-like composition for external preparations
JP2007269691A (en) * 2006-03-31 2007-10-18 Kose Corp Oily cosmetic
JP2012509870A (en) * 2008-11-25 2012-04-26 オキシジェン・バイオセラピューティクス・インコーポレイティド Perfluorocarbon gel formulation
JP2014073971A (en) * 2012-10-02 2014-04-24 Asahi Kasei Chemicals Corp Emulsion, composition, cosmetic composition, and pharmaceutical composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11509843A (en) * 1995-07-24 1999-08-31 アライアンス ファーマシューティカル コーポレイション Reverse gel consisting of continuous fluorinated phase
JP2004075540A (en) * 2002-08-09 2004-03-11 Rohto Pharmaceut Co Ltd Gel-like composition for external preparations
JP2007269691A (en) * 2006-03-31 2007-10-18 Kose Corp Oily cosmetic
JP2012509870A (en) * 2008-11-25 2012-04-26 オキシジェン・バイオセラピューティクス・インコーポレイティド Perfluorocarbon gel formulation
JP2014073971A (en) * 2012-10-02 2014-04-24 Asahi Kasei Chemicals Corp Emulsion, composition, cosmetic composition, and pharmaceutical composition

Also Published As

Publication number Publication date
JP6878724B2 (en) 2021-06-02
JPWO2019017295A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
KR100457157B1 (en) Semi-fluorinated alkanes and their uses
JP3267292B2 (en) Amphiphilic fluorine derivatives with telomer structure; preparation and biomedical applications
JPH09503802A (en) Viscoelastic composition of fluorinated organic compound
JP2002514190A (en) α-Branched fluoroalkylcarbonyl fluoride and its derivatives
JP5488121B2 (en) Agents for promoting transdermal absorption and / or improving moisture retention, and cosmetics
JP6878724B2 (en) Gel-like composition
WO2008050676A1 (en) Suspension of ascorbic acid in glycerin and process for production thereof
JP2007204432A (en) Solubilized cosmetic
JP3690052B2 (en) Oil gelling agent
EP3335692A1 (en) Method for preparing high-water-content emulsion gel using oil gel-forming agent
Kaplánek et al. Novel perfluoroalkylated oligo (oxyethylene) methyl ethers with high hemocompatibility and excellent co-emulsifying properties for potential biomedical uses
WO1998001104A1 (en) Cosmetic preparations containing fluorinated oils
WO2014061467A1 (en) Liquid composition
US7091374B1 (en) Fluorinated compounds
CA3037593A1 (en) Pharmaceutical composition comprising polyunsaturated long-chain ketones in a silicone vehicle
JP2003176318A (en) Radical-polymerizable 2-imidazoline derivative and method for producing the same
JPWO2007046318A1 (en) External liquid containing indomethacin
KR101249687B1 (en) Crosslinked copolymer based on monomer containing phosphorylcholine-like group, inverse emulsion, and cosmetic composition
KR20130071517A (en) Manufacturing method of solvent-free crosslinked copolymer based on monomers containing phosphorylcholine-like groups, and their cosmetic formulations
JP2004196767A (en) Cosmetic
JP2004115502A5 (en)
KR20160073326A (en) Polymer
JP2000344618A (en) Cosmetic and fluorine-containing compound

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18835393

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019531011

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18835393

Country of ref document: EP

Kind code of ref document: A1